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ABSTRACT 
 
Cell-penetrating peptides (CPPs) enter cells primarily through escaping from 
endosomal compartments or directly translocating across the plasma membrane. Due to 
their capability of permeating into the cytosolic space of the cell, CPPs are utilized for the 
delivery of cell-impermeable molecules. However, the fundamental mechanisms and 
parameters managing the penetration of CPPs and their cargos through the lipid bilayer 
have not been fully determined. This hampers their usage as a tool to study biological 
processes as well as for future therapeutic applications. In this work, I report the first 
observation that the cell penetration of linear polyarginine CPPs is dependent on the 
cellular oxidation state. Peptide delivery efficiency and the entry mechanism were 
evaluated in live human cells using fluorescence microscopy and flow cytometry. 
Additionally, lipophilic fluorescent probes were employed to detect the cell membrane 
oxidation level. Lastly, the mechanism of peptides penetrating the oxidized membrane 
was studied using live cells and in vitro partitioning assays.   
The presence of antioxidants and a hypoxic environment reduced the cell 
penetration of polyarginine CPPs. In contrast, oxidants promoted cytosolic entry with an 
efficiency proportional to the level of reactive oxygen species (ROS) generated within 
membranes. Moreover, a monoclonal antibody that recognizes oxidized lipids inhibited 
peptide penetration while extracellularly supplemented pure anionic oxidized lipids 
enhanced peptide transport into cells. The results support a model in which positively-
charged peptides bind negatively-charged lipids present on the cell surface as a result of 
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oxidative damage and cross the membrane via formation of inverted micelles. This may 
explain the variability in the cell delivery efficiency of a CPP in different experiments. 
These new findings therefore also provide opportunities for the design of future cell-
permeable compounds and for optimization of delivery protocols. 
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NOMENCLATURE 
 
BMP bis(monoacylglycero)phosphate 
BODIPY boron-dipyrromethene 
CBD chitin binding domain 
CHCA α-cyano-4-hydroxycinnamic acid 
CHO Chinese hamster ovary 
CPP cell-penetrating peptide 
cumene-OOH cumene hydroperoxide 
CytD cytochalasin D 
DC dendritic cell 
DEAC 7-diethylaminocoumarin 
dH2O distilled water  
DIEA N,N-Diisopropylethylamine 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOPS 1,2-dioleoyl-sn-glycero-3-phospho-L-serine 
DPPP diphenyl 1-pyrenylphosphine 
EGF epidermal growth factor 
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EGFP enhanced green fluorescent protein 
EIPA 5-(N-ethyl-N-isopropyl)amirolide 
EMCCD electron-multiplying charge-coupled device 
FBS fetal bovine serum 
FPLC fast protein liquid chromatography 
GAGs glycosaminoglycans 
GFP green fluorescent protein 
GPMVs giant plasma membrane vesicles 
GPx glutathione peroxidase 
H• hydrogen atom with an unpaired electron 
H2O2 hydrogen peroxide 
H9 nona-histidine 
HA hemagglutinin 
HBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
HDF human dermal fibroblast 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV-1 human immunodeficiency virus type 1 
HPLC high performance liquid chromatography 
HPMA N-(2-hydroxypropyl)methacrylamide  
HS heparan sulfate 
HSPGs heparan sulfate proteoglycans 
K9 nona-lysine 
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Kd disassociation constant  
Klf4 Krüppel-like factor 4 
L• lipid radical 
LH unsaturated fatty acid 
LOO• lipoperoxyl radical 
LOOH lipid hydroperoxide 
LPS lipopolysaccharides 
MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight 
MDA malondialdehyde 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MTX methotrexate 
NBD NF-κB essential modulator binding domain 
NS not significant 
O9 nona-ornithine 
Oct4 octamer-binding transcription factor 4 
OVA ovalbumin 
oxPC oxidized phosphatidylcholine 
PAD pro-apoptotic domain 
PazePC 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine 
PBS phosphate buffered saline 
PCI photochemical internalization 
PGPC 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine 
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PKI protein kinase inhibitor 
PNA peptide nucleic acid 
P/S penicillin/streptomycin  
PC phosphatidylcholine  
PE phosphatidylethanolamine 
POVPC 1-palmitoyl-2-(5’-oxo-valeroyl)-sn-glycero-3-phosphocholine  
PoxnoPC 1-palmitoyl-2-(9’-oxo-valeroyl)-sn-glycero-3-phosphocholine 
PS phosphatidylserine 
PTDs protein transduction domains 
R4 tetra-arginine peptide 
R8 octa-arginine peptide 
R9 nona-arginine peptide 
RBCs red blood cells 
RFP red fluorescent protein 
ROS reactive oxygen species 
Ru(II) Ruthenium(II) 
SDC4 syndecan-4 
siRNA small interfering RNA 
SOD superoxide dismutase 
Sox2 sex determining region Y- box 2 
SPPS solid-phase peptide synthesis 
TALEN transcription activator-like effector nucleases 
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TAT trans-activator of transcription 
TFA trifluoroacetic acid 
TIS triisopropylsilane 
TMR tetramethylrhodamine 
TPC 5-(4-carboxyphenyl)-10,15,20-triphenyl-2,3-dihydroxychlorin 
tRBCs trypsinized red blood cells 
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1. INTRODUCTION 
 
1.1. Significance of biomolecule delivery 
Delivery of exogenous biomolecules into cells is significant for applications in cell 
biology studies and therapeutic treatments. Two notable examples are delivery of 
transcription factors to reprogram stem cells and transport of oligonucleotides to repair 
gene alterations. Both applications along with others, however, have experienced 
inefficient cell penetration of cargo into the cytoplasm and cell nuclei. This is due to the 
hydrophobic nature of plasma membrane, which selectively filters the entry of 
extracellular molecules. Biomolecules are generally hydrophilic and large that cannot 
penetrate the lipid bilayer without the assistance of membrane transporters1. The cell 
membrane is therefore a hurdle to overcome in order to transport the biomolecules to their 
cytosolic targets. Electroporation and microinjection are two traditional physical 
approaches to achieve cytosolic delivery. Yet, their utilization to transport bioactive 
molecule is limited by their high cytotoxicity, delivery inefficiency, and high labor 
intensive requirements2. In contrast, macromolecules can be distributed intracellularly 
using a viral vector with high efficiency. However, this biological method has a high risk 
of insertion of viral DNA into the host genome2. Over the past twenty years, cell-
penetrating peptides (CPPs) have become promising carriers to deliver various 
biomolecules into cells3.    
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1.2. Cell-penetrating peptides as delivery carriers: focusing on polyarginine 
peptides 
1.2.1. History of cell-penetrating peptides 
As early as the 1960’s, researchers observed that polylysine facilitates the cellular 
internalization of covalently conjugated or co-incubated albumin proteins4, 5. In 1988, two 
independent research groups, Loewenstein and Pabo, both detected the activation of 
microinjected viral polynucleotides in human cells by adding the trans-activator of 
transcription (TAT) protein from human immunodeficiency virus type 1 (HIV-1) to the 
cell culture medium6, 7. These results suggested an unexpected membrane translocation 
activity of a hydrophilic macromolecule. The effective peptide sequence of TAT protein 
that is essential for its membrane transport activity was later identified to be 
RKKRRQRRR (residues 49 to 57)8-10. Similarly, the Drosophila Antennapedia 
homeoprotein with a trans-activating function was also shown to penetrate cells11. Its 16-
amino acid sequence, RQIKIWFQNRRMKWKK (residues 43 to 58, also known as 
Penetratin peptide), was responsible for the cell-penetrating activity12. Since then, around 
800 different peptide sequences have been reported to be able to transport into cells along 
with their carried cargo13. These peptides are therefore called CPPs or protein transduction 
domains (PTDs). 
 
1.2.2. Characteristics of cell-penetrating peptides 
CPPs are short polypeptides (generally 5 to 30 amino acids) that carry cargo with 
a wide range of sizes, from small-molecule compounds and short peptides to large 
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molecules such as proteins, polynucleotides, and nanoparticles, into the cytoplasmic space 
of live cells without causing cell death. Cargo delivery can be achieved by covalent 
attachment of a CPP to a cargo of interest or simply by co-incubation. Most CPPs show 
no cell specificity as the peptides penetrate various cell types including plant, insect, and 
stem cells, as well as both cancerous and noncancerous cells14-19.  
CPPs can be classified into three groups by their origin: protein-derived, chimeric, 
and synthetic20, 21. Protein-derived CPPs are peptides that originate from native protein 
sequences. Model peptides in this group are TAT and penetratin. Peptides fused from two 
or more natural peptide sequences are chimeric CPPs. Two of the best known examples 
are HA2-TAT, composed of HA2 peptide derived from hemagglutinin (HA) protein of 
influenza virus and TAT peptide22, 23, and transportan, a fusion peptide of galanin 
neuropeptide and mastoparan toxin peptide from wasp venom24. The third group consist 
of synthetic CPPs which are developed from rational design and mutational analysis. 
GALA, KALA, and polyarginines are among the best known representatives25, 26.  
From the prospective of physicochemical properties in the sequence, CPPs can 
also be grouped into two categories: cationic and amphipathic. Cationic CPPs contain a 
cluster of cationic amino acids, such as arginine and lysine. TAT and polyarginine peptide 
are two prototypical examples. Due to the high pKa values of arginine and lysine side 
chains, these peptides bear high positive charges in the physiological environment (pH 
7.4). On the other hand, amphipathic CPPs possess both hydrophobic and hydrophilic 
stretches in their sequences. The most studied constructs are HA2-TAT, KALA, and 
GALA. The net charge of these peptides varies and is dependent upon residue 
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compositions. Unlike cationic CPPs carrying no apparent secondary structures, most 
amphipathic peptides adopt an α-helical or β-sheet conformation upon binding to the 
membrane27. Recently two anionic peptides, which were considered to be cell-
impermeable due to their unfavorable overall negative charge, were reported to be able to 
traverse cell membrane28, 29.  
An emerging group of peptides displaying the cell-penetrating activities is cyclic 
peptides30, 31. This type of peptide contains at least one ring, synthesized by side chain-to-
side chain, terminus-to-terminus or side chain-to-terminus linkage32. The stapled peptide 
is a famous example in this category where the peptide gains cell permeability through 
“stapling” the side chains of the linear sequence33. The stapling method has been shown 
to increase and stabilize the α-helicity of peptide; however, that does not correlate with its 
membrane penetrating activity34, 35. Yet, multiple studies have demonstrated that the 
cyclized version of CPPs are even more potent in cell delivery than their linear 
counterparts35-37.  
 
1.2.3. “Arginine magic” of cell-penetrating peptides 
The significance of arginine residues in the TAT peptide sequence contributing to 
cell penetrating activity was established by the mutational analyses led by Wender, 
Rothbard and Futaki10, 38, 39. Wender found that nona-arginine peptide (R9), a homogenous 
arginine analog of TAT peptide, is efficiently internalized into Jurkat cells. This activity 
declined with decreasing number of arginine residues in the peptide sequence10. Similarly, 
Rothbard showed that other polycationic peptides, nona-lysine (K9), nona-histidine (H9), 
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and nona-ornithine (O9), failed to translocate into the cells38.  However, results of these 
two studies were obtained by flow cytometry analysis which can not differentiate 
cytosolically penetrated peptides from peptides entrapped in the endocytic pathways or 
sticking to the cell membranes40 (the detailed cell entry mechanism of polyarginine CPPs 
will be discussed in the next section). Futaki, on the other hand, investigated the cell 
penetrating activities of polyarginine peptides using fluorescence microscopy. The octa-
arginine peptide (R8) displayed a cytosolic distribution and nuclear staining after cell 
delivery, while the shorter peptide, tetra-arginine peptide (R4), showed no activity39. 
Unfortunately, this result was acquired from cells after fixation, which later was 
demonstrated to be able to stimulate the artificial cell membrane translocation of CPPs40, 
41. Though results from these pioneering studies were inconclusive, in 2003 polyarginine 
peptides were shown to have promising cytosolic penetration in live cells detected by 
fluorescence microscopy42, 43.  
The cell penetrating activity of polyarginine peptides is generally chirality-
independent, as both L- and D-arginine polypeptides can internalize into most live cells 
and tissues10, 38, 44-46. On the other hand, the activity is length-dependent such that the 
longer polyarginine peptides (R10, R11, R12) can achieve higher activities at the same or 
lower concentrations without increasing cytotoxicity comparing to the shorter peptides 
(R7, R8 and R9)47, 48, except that a much longer peptide (with more than 15 arginine 
residues) loses activity presumably by sticking to the cell membranes38, 49. Interestingly, 
peptides lose cell delivery activity when lysine residues are substituted for arginine, even 
with lengthy peptides such as K12 or K1638, 47, 50, 51.  This revealed that the overall cationic 
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charges alone are not sufficient to provide membrane translocation activity, as the amino 
group of lysine side chain is also positively charged at physiological pH (pH 7). This 
phenomenon can be explained by the model that the guanidinium moiety of arginine pairs 
bidentate hydrogen bonding with the anionic groups, such as phosphate, sulfate, and 
carboxylate, on the membrane components, while only monodentate hydrogen bonding 
can be formed by the ammonium of lysine52-54. This hypothesis was supported by the 
observation that the polyarginine peptide has a smaller disassociation constant (Kd) 
towards anionic membranes than the polylysine peptide55 and that the cellular uptake of 
polyarginine was greatly reduced when the guanidino group was methylated56. Moreover, 
grafting the guanidinium moiety or arginine residue-like side chains into the delivery 
vector have displayed superior cell uptake or penetration activities10, 38, 43, 57-61.  
 
1.3. Cell entry mechanism of polyarginine peptides 
The route and underlying mechanism by which an extracellular CPP enters the 
cytosolic space of a cell remains a matter of debate in the field. It is, however, widely 
accepted that the peptide can penetrate the cell by two routes. The first route is endocytosis 
followed by endosomal escape62-67. This is a two-step process involving endocytic uptake 
of the peptides upon binding to the cell surface and translocation across the membranes of 
the endocytic compartments. The majority of CPPs, not limited to polyarginine peptides, 
penetrate the cells and deliver their carried cargo via this pathway. Another route is a 
single step process in which the peptide transverses the lipid bilayer directly at the plasma 
membrane of the cell65, 68-70. This pathway was only observed in a few CPPs, including 
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polyarginine peptides. The evidence supporting the molecular mechanisms by which the 
polyarginine peptide permeates the cell membrane via these two distinct routes will be 
discussed in greater detail.     
 
1.3.1. Endocytosis and endosomolysis 
The current model of the cytosolic entry of CPPs and their cargo through endocytic 
pathways involves four major stages (Figure 1-1)62. First, the peptides bind to the cell 
surface. Next, the binding promotes the endocytic internalization of the peptides into 
transport vesicles. Third, the peptides in the vesicles travel along the endocytic pathways. 
Finally, the CPPs translocate across the membranes of the endocytic compartments and 
reach the cell cytosol. The molecular details of each step will be discussed, focusing on 
studies with polyarginine peptides.    
Accumulating evidence suggests that, as in the first step, the ability of polyarginine 
peptides to interact with the mammalian cell plasma membrane is due to binding to the 
cell-surface glycosaminoglycans (GAGs), specifically from heparan sulfate proteoglycans 
(HSPGs)71. HSPGs are membrane-anchored glycoproteins that contain one or more 
heparan sulfate (HS) chains that are exposed extracellularly72. Due to the abundance and 
negative charge that is contributed by sulfates and carboxylates (structure shown in Figure 
1-1), it is believed that the endocytosis is triggered upon binding and clustering between 
cationic polyarginine peptides and anionic HSPGs. This model is supported by the results 
that nona-arginine peptides are unable to internalize into HS-deficient cell lines63, 73 and 
that the cellular uptake of the octa-arginine peptide is increased when syndecan-4 (SDC4),  
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Figure 1-1. Model of the trafficking of a CPP-cargo conjugate through the endocytic 
pathway. From left to right: A CPP-cargo binds to heparan sulfate proteoglycans (HSPGs) 
on the cell surface and induces endocytosis. Endocytosis leads to uptake and entrapment 
of the CPP-cargo inside an endocytic vesicle. The endosomal membrane contains 
phosphatidylserine (PS) in its outer leaflet. During endosomal maturation, a vacuolar H+-
ATPase acidifies the lumen of endocytic organelles. The CPP-cargo reaches early 
endosomes (pH~6.5). Concurrently, hydrolases partially degrade HSPGs and release 
heparan sulfate (HS) fragments. Upon further maturation, the CPP-cargo reaches 
multivesicular bodies, late endosomes (pH~5.5), and lysosomes (pH~4.5). The membrane 
of the intraluminal vesicles of late endosomes is enriched with phospholipid 
bis(monoacylglycero)phosphate (BMP). HS is further degraded to smaller fragments. The 
CPP-cargo is susceptible to degradation due to the low pH and lysosomal hydrolases. The 
figure is used with permission62.  
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a HSPG protein, was overexpressed74. Moreover, in the in vitro assays, the peptides show 
a high affinity to HS or to the analog heparin with a Kd of between 100 and 320 nM
63, 75-
78. Notably, the polyarginine peptides also show strong interactions with anionic lipids55, 
79, 80. However, considering the relatively low abundance of anionic lipid species (less than 
10% of the total lipids)81-83 and the lipid asymmetry of plasma membrane84, 85, the high 
density of GAGs (the molar ratio of total GAGs to total lipids is about 1:15)86, 87, similar 
binding affinities of the peptide to GAGs and to negatively charged lipids55, 63, 75, 76, and 
no in cellulo experimental proof, all these facts make it unlikely that lipids are the primary 
binding target of the peptides at the plasma membrane of mammalian cell which initiates 
endocytosis. Yet, lipids were suggested to play an important role in assisting the 
translocation of the peptide directly across the plasma membrane, which will be 
introduced in the next section. Interestingly, proteins located at the plasma membrane were 
recently reported to play roles in the endocytic entry of polyarginine peptides88, 89.    
Unlike some other CPPs which are internalized in endocytic vesicles via caveolae-
mediated or clathrin-mediated endocytosis upon binding to the cell plasma membrane, the 
polyarginine peptides enter cells mainly via macropinocytosis. This notion is supported 
by the results that the cellular uptake of the peptides was reduced when treating cells with 
macropinocytosis inhibitor 5-(N-ethyl-N-isopropyl)amirolide (EIPA)49, 90. Furthermore, it 
has been shown that membrane ruffles and the rearrangement of actin filaments are 
involved in the process of macropinocytosis91, 92. With the presence of the membrane 
ruffling inducer, epidermal growth factor (EGF), or F-actin depolymerizor, cytochalasin 
D (CytD), the cellular internalization of the peptide significantly increases or decreases, 
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respectively49. Yet, the cell delivery efficiency of polyarginine peptide was insignificantly 
affected by macropinocytosis inhibitor EIPA in some cells lines, leaving the endocytosis 
mechanism a matter of debate93-95. However, the cellular uptake of polyarginines is 
certainly reduced by other endocytic pathway inhibitors 49, 94-96. Moreover, when arresting 
all cellular endocytic processes by incubating cells at low temperature (4-22oC) without 
causing cytotoxicity, the peptide fails to internalize into the cells at the same level93, 97, 98. 
All together, these data suggest that endocytosis, presumably macropinocytosis, is the 
major endocytic route of cell entry of the peptide.   
Live-cell experiments have confirmed that polyarginines trafficking within 
endocytic vesicles. Under microscopic examination, the endosome-like vesicular 
structures were observed to fuse with organelles containing the peptide signal49. 
Furthermore, the cells loaded with the endocytic pathway marker, dextran, or expressed 
with the fluorescently labeled early or late endosomal proteins, Rab-5 or Rab-7, have 
shown co-localization with the peptide93, 96. Inhibition of microtubules by a 
depolymerizing compound, nocodazole, also affects the internalization of the peptide49, 93. 
When trafficking along the endocytic pathways, the polyarginine peptides and their cargo 
can escape from the vesicles to reach targets in the cytoplasm or nucleus. The molecular 
mechanism of the endosomal release of polyarginine peptides, however, is still unresolved. 
This could result from the inefficient endosomolytic activity of the peptide99-104, which 
makes their study difficult.   
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1.3.2. Direct plasma membrane translocation 
Aside from endocytic entry, polyarginines can directly permeate the lipid bilayer 
in a non-endocytic fashion at the plasma membrane of live cells. Cells treated with 
endocytic inhibitors or incubated at low temperature, in order to impair cellular 
endocytosis including macropinocytosis, still were still found to take up polyarginine 
peptides42, 45, 94, 105-108. However, the validity of these results was questioned by 
specificities of the inhibitors as well as their impacts on cell physiology109, 110. Most of the 
experiments also did not include proper controls to validate the effectiveness of inhibition 
treatments. Yet, lines of evidences, such as the fast cytosolic entry of polyarginine peptides 
and formation of multivesicular peptide-membrane complexed structures at the plasma 
membrane upon peptide delivery, strongly support the direct plasma membrane 
translocation model70, 105, 107, 111. Moreover, the peptide can penetrate proteo-liposomes 
derived from cell plasma membrane, named giant plasma membrane vesicles (GPMVs) 
that retain similar lipidic and proteinaceous components of plasma membrane, with the 
inability of endocytosis112, 113. This result confirms that endocytosis is not required for 
penetration. The direct membrane penetration of the peptide was also observed with 
liposomes composed of anionic lipids51.   
The mechanism by which the polyarginine peptides penetrate through the plasma 
membrane is still largely inconclusive. Several models were proposed, including that 
penetration with the assistance of membrane potential difference across the membrane by 
Wender and Herce14, 56. Brock suggested that the translocation occurred at nucleation 
zones that were involved in the formation of ceramide-enriched domains111. The 
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nucleation zone model is in agreement with the observation of multivesicular peptide-lipid 
structure published by Futaki70.         
 
1.4. Roadblocks of cell delivery using polyarginine CPPs 
Despite the promise of the broad utility of polyarginine CPPs to intracellularly 
deliver bioactive cargo in cellulo and in vivo46, 114-130, general rules of cytosolic penetration 
have not yet clearly been established. In some instances, cytosolic penetration appears to 
be involved in direct plasma membrane translocation. Alternatively, a two-step process of 
endocytosis followed by escape from endosomes has also been observed. It is currently 
plausible that polyarginine CPPs utilize these two distinct routes of cellular entry to 
varying degrees. Additionally, molecular details that explain how a peptide crosses 
cellular membranes are also lacking. A wide variety of translocation models have been 
proposed, most of which highlight the ability of polyarginine CPPs to interact with lipid 
bilayers14, 70, 111, 131-133. These mechanisms, while potentially non-exclusive, remain a 
matter of debate. 
In the absence of understanding the parameters that control cytosolic penetration 
and the mechanistic insights of a peptide traversing across the lipid bilayer, designing 
better delivery tools or strategies often replies on a process of trial and error. It is clear 
that the peptide concentration, number of arginine residues, cell types, and physical-
chemical properties of the cargo impact the delivery route 68, 129, 134, 135. Moreover, the 
results obtained with polyarginine CPPs are often unpredictable with high variability in 
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cytosolic penetration (Table 1-1). In particular, minor changes in experimental conditions 
can impact the results obtained, indicating that unknown variables modulate this process. 
Table 1-1. Polyarginine peptides, cargo, and cell line utilized in the selected 
publications 
Peptide Cell Line Cargo Ref. 
R3-R9, R15, R20, 
R25, R30; r4-r9 
Jurkat fluorescein 38
R7 Jurkat Cyclosporin A 130
R5-R9 Jurkat fluorescein 10
R4, R8, R12, R16 COS-7 plasmid 136
R4, R6, R8, R10, 
R12, R16 
RAW264.7 fluorescein 39
R7, R9, R11 COS-7, C2C12, U251-
MG, PC12, primary 
neurons 
EGFP, PKI peptide, 
fluorescein 
135
R8 HeLa fluorescein 137
R4, R6, R8, R10, 
R12 
CHO-K1, HIG-82, HeLa, 
A549, Jurkat, pgsD-677, 
pgsA-745 
streptavidin-β-galactosidase, 
Streptavidin-Alexa Fluor 
488 
129
R7 primary keratinocytes biotin, HA peptide 138
R7, R10; r7, r13 Jurkat fluorescein 48
R8, R16 RAW264.7, HeLa, COS-
7 
TMR 139
R11 SAOS-2, NOS-1, SAS, 
HSC-3, HSC-4 
p53 140
r5, r7, r9 Jurkat fluorescein 57
R9 10T1/2, HeLa BODIPY, fluorescein 
43
R8 CHO GFP 41
R7 COS-7 plasmid 141
R9 MC57 fluorescein 142
R9 CHO-K1, pgsD-677, 
pgsA-745 
TMR 63
R8 NIH/3T3 fluorescein, plasmid 143
R4, R8, R16; r8 HeLa Texas Red, fluorescein, PAD 
peptide 
49
r8 Jurkat fluorescein 56
R9 CHO biotin 144
14 
Table 1-1. Continued 
R11 A549, HeLa, CHO-K1 TMR, PKI peptide, NBD 
peptide  
145
R11 U251-MG, KR158 p53 101
R6, R7, R9 HeLa peptide nucleic acid (PNA) 146
R8 K562, KG1a Alexa Fluor 488, Texas Red 93
R7 MDA-MB-468 5-(4-carboxyphenyl)-
10,15,20-triphenyl-2,3-
dihydroxychlorin (TPC) 
147
R9 dendritic cell (DC) ovalbumin (OVA), HA 
peptide 
127
R7; r6, r7, r8, r9 HeLa, p53R PNA 148
R8 HeLa Alexa Fluor 488, EGFP, 
PAD peptide 
100
R9 HeLa, MC57, CHO, 
dendritic cell, Jurkat 
fluorescein, Smac peptide 94
R8; r8 KG1a Alexa Fluor 488 45
R9 HeLa N/A 149
R4, R6, R8 HL-60 Ferrocenecarboxylic acid 125
R8 CHO-K1, pgsD-677, 
pgsA-745, 293T 
Alexa Fluor 488 150
r8 Jurkat luciferin 151
r4, r8 UCI-101, UCI-107, 
SCOV-3, OVCA-429, 
OVCA-433, MCF-7 
Taxol, coelenterazine, 
luciferin 
126
R4, R8, R12, R16 HeLa, CHO-K1, pgsA-
745 
Alexa Fluor 488, PAD 
peptide 
107
R5-R12 C2C12, Wistar, HeLa, 
MDCKII, BJ-hTERT 
fluorescein, TMR 47
R9 HeLa fluorescein 152
R9 HeLa Fluorescein, oligonucleotide 
mixmer 
153
R9 A549 GFP, RFP, mCherry 154
R9 CHO-K1, pgsA-745 biotin 106
R9 HEK293 Klf4, c-Myc, Oct4, Sox2 124
r8 HeLa Ru(II) dipyridophenazine  104
R8 HeLa Alexa Fluor 488 99
R8 KG1a, KG1, K562, A549 Alexa Fluor 488 105
R11 MEF Klf4, c-Myc, Oct4, Sox2 122
R4, R6, R8 HL-60 17-desacetylvinblastineTrp 121
R8 K562 fluorescein, Alexa Fluor 555 74
Peptide Cell Line Cargo Ref. 
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Table 1-1. Continued 
R9 HeLa HPMA polymer, Smac 
peptide 
111
r9 HEK293, H9c2, L2 plasmid 155
R8 iPS cells Texas Red 120
R7, R9 A549 plasmid 156
r8 NIH/3T3 fluorescein 157
r10 C2C12 fluorescein 36
R9 C6, B16F10, MDA-MB-
231, MCF-7 
fluorescein 158
R9 CHO TMR, fluorescein labeled 
dextran 
159
R16 CHO-K1, pgsA-745 plasmid, fluorescein 50
R9 HeLa TMR 160
R9 HEK293T NBD 60
R9; r9 HeLa, MC57, Jurkat fluorescein 161
R9 CHO-K1, pgsA-745 biotin 98
R8 HeLa, A431 Alexa Fluor 488, siRNA, 
FITC-Dex40, TMR-Dex70 
95
R8 HeLa TMR, fluorescein, 
dexamethasone 
96
R4, R12 HeLa Alexa Fluor 488, HAtag 70
R3, R5, R7, R9, 
R11 
U251-MG, mouse 
primary fibroblast, H520, 
U87MG, LNZ308, K562 
TMR, EGFP, p53 162
r9 HeLa, Lovo, A549, 
MCF7, U2OS, HepG2, 
K562, NHDF, primary 
AML cells, PBMC, 
AML3639, primary colon 
adenocarcinoma cells,  
fluorescein 163
R11 HEK293, HeLa fluorescein 164
R8; r8; rR7; 
(rR)2R4; (rR)3R2; 
(rR)4; r2(rR)3 
HeLa fluorescein 165
R6 Huh7.5 siRNA 166
R8; r8, r12 HeLa, T98G Alexa Fluor 488, FITC-Dex-
70, p53C’ peptide, p27Kip1C 
peptide, PAD peptide 
103
R4, R12 CHO-K1, HeLa Alexa Fluor 568 88
R5, R7, R9, R11 A549 plasmid 118
R9 CHO TMR 97
Peptide Cell Line Cargo Ref. 
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Table 1-1. Continued 
R9 A549 quantum dots 167
R8 HeLa fluorescein, saporin 102
R9 HeLa fluorescein 168
R9 HeLa, HEK293 TALEN 117
R8 HeLa Alexa Fluor 488 169
R9 HeLa fluorescein, siRNA 89
R9 CHO-K1, pgsA-745 biotin 73
R8 T98G, PNA 170
R8, R15 CHO-K1 siRNA 171
R9 PT45, HepG2 Fluorescein, ferrocene, 
ruthenocene 
172
R8 HeLa Lissamine rhodamine B 173
R9; r9 TE671 Cre recombinase, biotin 174
R9 HeLa TMR 175
R9 Huh-7, HeLa plasmid 116
R9 Jurkat FITC-siRNA 176
R6, R7, R8, R9 HeLa fluorescein 177
R11 T24 fluorescein, p53C peptide, 
Con peptide 
114
R9 A549, HEK293 plasmid 178
R8 HeLa fluorescein 179
R8; r8 Caco-2 nanoparticle 180
R8 HeLa Alexa Fluor 488, TMR, Cre 
recombinase 
181
R9 Huh-7, HeLa TMR, plasmid 182
R9 MA-104, Caco-2 Fluorescein 183
R8 MCF-7, MDA-MB-231 methotrexate (MTX), 
fluorescein 
184
Peptide Cell Line Cargo Ref. 
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1.5. Membrane oxidation and its role in membrane translocation activity 
The delivery efficiencies of polyarginine CPPs are often sub-optimal such that 
most of associated cargo remains trapped in the endocytic organelles. One approach to 
overcome this problem is to enhance endosomal release by light irradiation, also known 
as photochemical internalization (PCI)160, 185, 186. Upon exciting the photosensitizer 
conjugated to the CPPs, generated reactive oxygen species (ROS) oxidize the adjacent 
membrane which leads to the efficient translocation of the peptide. With the 
photosensitizer alone, the inability to permeabilize the lipid bilayer indicates the 
importance of interactions between the CPPs and oxidized membrane components in the 
translocation activity55, 160, 187.   
The oxidation of the membrane can be induced by artificial photoradiation, but can 
also take place under physiological conditions. Lipid peroxidation has been shown to exist 
under physiological conditions and relates to the development of cardiovascular disease, 
diabetes, renal dysfunction, neurological disorders, lung injury and cancer188-190. Oxidized 
lipids also play important roles in modulating intracellular signaling and serving as 
markers for innate and adaptive immune recognition189. Cellular antioxidants, such as 
ascorbic acid and α-tocopherol, and detoxifying enzymes, such as superoxide dismutase 
(SOD) and glutathione peroxidase (GPx) can prevent the initiation and progression of 
oxidative damage191, 192. It has been shown that oxidized membrane components enhance 
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the electropermeabilization of the membrane. Cells treated with oxidizing compounds 
displayed greater electroporation efficiency193, 194.  Results obtained from in vitro and in 
silico studies suggest that the generation of oxidized phospholipids, as a result of 
membrane oxidation, altered membrane fluidity and permeability195-197.    
1.6. Goal of this study 
Membrane oxidation has been shown to play a role in the efficiency of membrane 
permeation in electroporation and as a way to translocate across the membrane by photo-
induction. It is, however, unclear how innate membrane oxidation levels would correlate 
to the delivery efficiency of polyarginine CPPs. In order to address this issue, this study 
first focused on identifying a highly efficient polyarginine CPP and established its cellular 
entry route. Whether the cellular membrane oxidation level affects peptide penetrating 
activity will be evaluated in cultured cells, by altering the surrounding cellular oxidative 
stresses. The cell membrane oxidation level under different culture conditions was 
quantitatively analyzed with a fluorescent probe. Moreover, the important component of 
oxidized membrane that involves in the mediation of membrane translocation of the 
peptide was analyzed in cellulo and in vitro. 
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2. MEMBRANE OXIDATION MEDIATES DIRECT PLASMA MEMBRANE 
TRANSLOCATION OF CELL-PENETRATING PEPTIDES1  
 
2.1. Introduction 
It is well appreciated that oxidation occurs during typical tissue culture growth 
conditions and that oxidized lipids and proteins are physiologically relevant components 
of cellular membranes198, 199. In principle, the relative abundance of these species varies 
depending on the level of oxidative stress attacking cells and on the efficiency of various 
repair mechanisms. Membrane oxidation has already been shown to affect transport 
processes such as viral infections, the diffusion of small-molecule drugs across lipid 
bilayers, or electroporation194, 200, 201. Based on these observations, I postulated that 
membrane oxidation might also modulate the cytosolic penetration of CPPs.  
 
2.2. Results 
2.2.1. Identification of efficient CPPs and robust cytosolic penetration assay 
To identify a CPP construct that would penetrate cells efficiently, I first 
synthesized a group of linear polyarginine peptides that contains an increasing number of 
arginine residues (from 5 to 13) and labeled them with the fluorophore 
tetramethylrhodamine (TMR) for monitoring the cytosolic penetration by using 
                                                 
1 Reprinted with permission from “Membrane oxidation enables the cytosolic entry of polyarginine cell-
penetrating peptides” by Wang, T.-Y., Sun, Y., Muthukrishnan, N., Erazo-Oliverase, A., Najjar, K., and 
Pellois, J.-P., 2016. The Journal of Biological Chemistry, 291(15): 7902-7914. Copyright 2016 by the 
American Society for Biochemistry and Molecular Biology. 
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fluorescence microscopy. Peptides were synthesized with all L or all D amino acids 
(named as L-CPPs or D-CPPs respectively) (Figure 2-1). The peptides containing seven 
or fewer arginines showed no apparent cytosolic penetration in human skin fibroblasts 
(human dermal fibroblast, HDF, and immortalized human skin fibroblast, MCH58). In 
contrast, the peptide with 9 arginine residues displayed cytosolic penetration in MCH58 
cells but not in HDF cells. Finally, peptides with 11 or 13 arginines displayed significant 
levels of cytosolic penetration in both cell types (Figure 2-2). Penetration was established 
by observing nucleolar staining by the peptides at high magnification (100X) (Figure 2-
3). This staining is common for arginine-rich peptides and, because cytosolic entry 
presumably precedes nucleolar staining, it indicates that CPPs reach the intracellular 
cytosolic/nuclear milieu70, 94, 107, 202, 203. Importantly, this specific staining was observable 
at 20X magnification for D-CPPs but not for L-CPPs (Figure 2-3). This is presumably 
because, unlike the protease-resistant D-CPPs, L-CPPs degrade rapidly inside cells.  
Consequently, the fluorescence associated with L-CPPs was more diffuse overall and 
nucleolar staining was not clearly detectable at low magnification. In turn, at low 
magnification the cytosolic/nucleolar signal could not be convincingly distinguished from 
unrelated signals (peptides inside endosomes, peptides bound to cell surface, etc.), making 
quantification of the penetration of L-CPPs problematic and unconvincing. In contrast, 
quantification of cell penetration was straightforward with D-CPPs as these reagents led 
to unequivocal nucleolar/cytosolic staining at a magnification compatible with surveying 
a large number of cells. I therefore focused on this class of reagent for the rest of the study 
and used a penetration assay that relies on simply counting the number of cells that show 
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nucleolar staining in a culture after incubation with peptides. In this assay, dead cells are 
identified by staining with the dye SYTOX Blue. Overall, cells displaying nucleolar 
staining and excluding SYTOX Blue are considered positive for peptide cytosolic 
penetration (presented as Penetration (+) (%) in Figures).  
 
 
 
Figure 2-1. Structures of TMR-Rn peptides. 
 
 
 
 
 
 
 
 22 
 
 
Figure 2-2. Delivery efficiencies of polyarginine peptides in HDF and MCH58 cells. 
To identify polyarginine CPPs with high cytosolic delivery efficiencies, HDF or MCH58 
cells were incubated with each peptides containing five to thirteen arginine residues 
(TMR-Rn, n = 5-13). The N-terminus of peptide was labeled with a red fluorophore, 
tetramethylrhodamine (TMR), in order to visualize the localization of the peptide inside 
the cell after delivery. The cells were incubated with 3 µM peptide for one hour at 37oC. 
After incubation, unincorporated peptides were removed by washing cells with PBS and 
heparin solution (1 mg/mL heparin sodium salt in L-15 medium) for three times. The cells 
were imaged with fluorescence microscope by detecting TMR fluorescence (RFP filter). 
Penetration (+) (%) was scored as the cells with distinct cytosolic distribution and nucleoli 
staining of the peptide but without nuclear staining of cell-impermeable dye SYTOX Blue. 
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Figure 2-3. Representative images of MCH58 cells incubated with the TMR-R13 or 
TMR-r13 peptide. TMR-R13 and TMR-r13 were synthesized with L-arginine (L-Arg) 
and D-arginine (D-Arg), respectively. Nucleolar staining can be seen with TMR-R13 
peptide at 100X magnification. However, this staining is less pronounced upon 20X 
imaging. In contrast, nucleolar staining is visible with the TMR-r13 peptide using both 
100X and 20X imaging (highlighted by arrows). The acquired images are inverted 
monochromes of TMR fluorescence emission (RFP filter). Scale bars, 20 µm.  
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As the most active compound in the series, TMR-r13, where r is the one letter code 
for D-Arg, was characterized in greater detail. The dose-dependence of TMR-r13 on 
penetration showed that the peptide penetrates both MCH58 and HDF cells equally 
efficiently at 5 µM or above (Figure 2-4). At lower concentrations, MCH58 are, however, 
more prone to penetration than HDF. Notably, cells examined were resistant to staining 
with SYTOX Blue and were variable and proliferating up to sixty hours after incubation 
with the peptide (Figure 2-5 and 2-6). The rate of proliferation of cells treated with TMR-
r13 was markedly lower than untreated cells, a phenomenon that I attribute to the 
prolonged retention of the protease-resistant CPP inside cells (unpublished data). Overall, 
TMR-r13 nonetheless displays a cytosolic penetration activity that is high, easily 
quantifiable, and non-toxic at the concentrations tested.  
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Figure 2-4. Cytosolic penetration efficiency and cytotoxicity of TMR-r13 peptide in 
MCH58 and HDF cells. Dose-dependence of the cytosolic penetration of TMR-r13. The 
efficiency of cytosolic penetration was measured in MCH58 and HDF cells as the 
percentage of cells positive for nucleolar peptide staining and negative for SYTOX Blue 
staining. The region marked in grey highlights how MCH58 cells are significantly more 
prone to cellular penetration than HDF cells at 1 µM of TMR-r13 peptide. *** represents 
P≤0.001 compared to HDF cells at the same peptide concentration.  
 
 
 
 
 
 26 
 
 
Figure 2-5. The proliferation rate of HDF cells treated with TMR-r13 peptide is 
reduced when compared to untreated cells. The cell proliferation of HDF cells were 
measured using the MTT assay. Detailed steps for performing MTT assay can be found in 
the method section. Briefly, cells were treated with 5 µM TMR-r13 for 1 hour at 37oC. 
After removing extracellular peptides, cells were cultured for up to 60 hours. The 
proliferation rate of cells were examined by measuring the production of formazan as an 
indicative of the enzymatic activity of a mitochondrial reductase. The measurement was 
carried out every 12 hours. The production of formazan was quantified by measuring the 
absorbance at 570 nm. Cells without pre-treating with TMR-r13 peptide serve as a control. 
* represents P≤0.05 compared to untreated cells. 
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Figure 2-6. Treatment of HDF and MCH58 cells with TMR-r13 peptide did not 
reduce cell viability. The cell viability of HDF and MCH58 cells after incubating with 
TMR-r13 was determined by SYTOX Blue exclusion assay. After peptide incubation, 
cells were incubated with 5 µM SYTOX Blue for 5 min. The signal distribution of SYTOX 
Blue inside the cells were determined by fluorescence microscope using CFP filter. Cells 
without staining with SYTOX Blue were considered as viable.  
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2.2.2. TMR-r13 peptide directly translocates across the plasma membrane 
In cells without a strong cytosolic/nucleolar signal, TMR-r13 can be seen trapped 
inside endosomes (Figure 2-7), indicating that TMR-r13 is capable of endocytosis. This 
mode of entry is common for arginine-rich CPPs as these compounds are often 
internalized by macropinocytosis. This then raises the question of whether endocytosis is 
a required step preceding cytosolic entry or whether it is a process occurring in parallel 
with an endocytosis-independent penetration mechanism. To address this, I first tested the 
effect of amiloride and bafilomycin, inhibitors of macropinocytosis and endosomal 
acidification, respectively, on cellular entry. These inhibitors did not decrease the 
cytosolic penetration activity of TMR-r13. Similarly, incubation with cells was performed 
at 4oC, a condition that inhibits energy-dependent endocytic uptake, only led to a minor 
reduction in cell penetration (Figure 2-8). In addition, cytosolic penetration was achieved 
in a relatively high percentage of cells within 1 or 3 min of incubation, making a process 
involving endocytosis and endosomal escape upon slow endocytic maturation unlikely 
(typical time frame varies from 5 to 30 min) (Figure 2-9)204. Furthermore, TMR-r13 did 
not cause the release of fluorescent material preloaded within endosomes (Figure 2-10 and 
2-11). In contrast, the positive control, dfTAT, an endosomolytic reagent, efficiently 
induced the endosomal escape of endocytosed material (Figure 2-11)17. This suggests that 
the cytosolic penetration of TMR-r13 does not involve leakage from the endocytic 
pathway. Overall, these data indicate that the peptide does not require endocytosis to gain 
access to the cytosol. In turn, exclusion of this possibility instead indicates that the peptide 
enters the cytosolic space by crossing the plasma membrane directly. To test whether the 
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plasma membrane translocation of the peptide enhanced the permeation of other 
molecules, TMR-r13 was co-incubated with fluorescent molecules of various sizes, 
including the small molecule SYTOX Green, fluorescently-labeled peptides (DEAC-k5, 
0.9 kDa), and macromolecule enhanced green fluorescent protein (EGFP, 26.8 kDa). 
While TMR-r13 entered cells in all assays, no other fluorescent materials could be 
detected within cells, indicating that the TMR-r13 mediated translocation was not 
accompanied by transient membrane leakage (Figure 2-12).  
 
 
Figure 2-7. TMR-r13 is capable of internalizing into HDF cells through endocytosis. 
In HDF cells, a cell type less prone to cell penetration, the peptide shows a punctate 
distribution. The image is the inverted monochrome of fluorescence emission of TMR. 
The zoomed-in images show co-localization of puncta (highlighted by arrows) containing 
TMR-r13 (pseudocolored red) and LysoTracker (pseudocolored green), suggesting 
entrapment of TMR-r13 in acidic endocytic organelles. Scale bar, 20 µm.  
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Figure 2-8. Inhibitors of endocytic processes do not prevent cytosolic penetration of 
TMR-r13 peptide. A, Scheme of inhibitory treatment on different endocytic processes. 
B, MCH58 cells were pretreated with 50 µM amiloride, 200 nM bafilomycin, or PBS 
supplemented with calcium and magnesium (no inhibitor, 37oC) for 20 min. Cells were 
then incubated with 1 µM TMR-r13 peptide in the presence of inhibitors for 1 hour. 
Alternatively, cells were maintained at 4oC during peptide incubation. NS (not significant) 
represents P>0.05 and * represents P≤0.05 compared to cells with no inhibitor at 37oC.  
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Figure 2-9. Fast cytosolic penetration of TMR-r13 peptide in MCH58 cells. MCH58 
cells were treated with 5 µM TMR-r13 peptide for the indicated times. Images are the 
overlay of bright field, TMR-r13 peptide (pseudocolored red) and SYTOX Blue 
(pseudocolored blue). A zoomed-in image shows distinct nucleolar staining of delivered 
TMR-r13 peptide without SYTOX Blue staining. Scale bar, 50 µm.  
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Figure 2-10. Entrapment of internalized DEAC-k5 peptide in the endocytic 
organelles of HDF cells. HDF cells were incubated with DEAC-k5 peptide (20 µM, 1 
hour, k is the one-letter code for D-lysine). The image is the inverted monochrome of 
fluorescence emission of DEAC. Accumulation of DEAC-k5 peptide (pseudocolored red) 
within endocytic vesicles after 1-hour incubation is established by co-localization with 
LysoTracker (pseudocolored green) (co-localization is highlighted by arrows in the 
zoomed-in images). Scale bar, 20 µm.  
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Figure 2-11. TMR-r13 peptide fails to release internalized DEAC-k5 peptide from 
endocytic pathway in HDF cells when the endosomolytic agent dfTAT peptide does. 
HDF cells were pre-incubated with 20 µM DEAC-k5 peptide for 1 hour. Cells were then 
treated with TMR-r13 or dfTAT peptide and imaged by fluorescence microscopy. The 
cells were not stained by SYTOX Green, indicating insignificant cytotoxicity after peptide 
delivery. The acquired images are inverted monochrome of fluorescence emission and 
monochrome of bright field imaging. Scale bar, 20 µm.   
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Figure 2-12. Membrane translocation by TMR-r13 peptide is not accompanied by 
penetration of the small molecule SYTOX Green or DEAC-K9 peptide. Cells were 
incubated for 1 hour at 37oC with both TMR-r13 peptide (1 µM) and SYTOX Green (5 
µM), a green fluorescent cell-impermeable nuclear staining dye that can enter cells upon 
permeation of the plasma membrane. After peptide delivery, cells were washed and 
incubated with SYTOX Blue, a nuclear stain similar to SYTOX Green but with an extinct 
excitation wavelength. TMR-r13 peptide penetrated cells while excluding both SYTOX 
Green and SYTOX Blue. Similar results were obtained when SYTOX Green was 
substituted for DEAC-K9 (an oligolysine peptide labeled with the blue fluorophore 
DEAC). Fluorescence images are represented as inverted monochrome. Scale bars, 20 µm.  
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2.2.3. Reduced oxidative stress decreases cytosolic penetration of TMR-r13  
The experiments described above were carried out with cells exposed to 20% 
oxygen during culture (ambient air supplemented with 5% carbon dioxide, standard 
protocol). If oxidation affects transport of the peptide across membranes as originally 
postulated, one would expect that reducing oxidative stress should decrease cytosolic 
penetration. In order to test this hypothesis, MCH58 cells were grown for a week at either 
20% oxygen or in a sealed chamber flushed with 2% oxygen, 5% carbon dioxide, and 93% 
nitrogen. MCH58 cells were chosen for this assay because they appear to be more prone 
to cell penetration than HDF cells and therefore provide a cell line more adequate for 
inhibition studies (Figure 2-3). Cells were then exposed to TMR-r13 peptide (1 µM) for 1 
hour and the number of cells positively displaying nucleolar staining was counted. Under 
these conditions, hypoxia did not appear to impact the percentage of cells positive for cell 
penetration (Figure 2-13). Yet, a more careful examination of the process showed 
significant differences when the incubation time with peptide was shorter (Figure 2-14). 
In addition, the overall amount of peptide entering cells, quantified by flow cytometry, 
was reduced when compared to 20% oxygen (Figure 2-14).  This indicates that while 
cytosolic penetration is still possible at low oxygen levels, this process is partially 
inhibited, as less peptide is able to enter cells. Assuming that cytosolic penetration might 
still be permitted by oxidized species that remain present even at low oxygen tension, I 
next added an antioxidant cocktail to the growth media to further reduce oxidative stress 
experienced by cells. This cocktail includes pyruvate, α-tocopherol, Trolox, ascorbic acid, 
2-phospho-L-ascorbic acid and sodium selenite. These species are either scavengers of 
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oxidants or cofactors of enzymes that deplete cells from oxidized species205-208. The 
antioxidant cocktail had a pronounced effect on reducing the percentage of cells positive 
for TMR-r13 peptide and, in combination with 2% oxygen, almost abolished cytosolic 
penetration (Figure 2-13).  
Because TMR-r13 peptide is the most active compound tested in our polyarginine 
series, I next examined how hypoxia would impact a less potent peptide (Figure 2-3). For 
this assay, TMR-r9 peptide was tested since nona-arginine CPPs that are widely used as 
delivery agents117, 124, 209. When using MCH58 cells grown at 20% oxygen, the TMR-r9 
peptide required an incubation concentration of 1 µM to achieve a penetration efficiency 
equivalent to that obtained with TMR-r13 peptide (approximately 65% penetration 
positive cells after 1 hour incubation). When these conditions were used with cells grown 
at 2% oxygen, the penetration of TMR-r9 peptide was abolished (Figure 2-15). Overall, 
this indicates that the impact of hypoxia is increasingly more pronounced as the potency 
of the CPP is reduced. Inversely, this also suggests that oxidative processes are required 
for the penetration of CPPs.   
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Figure 2-13. Conditions of reduced oxidative stress decrease cytosolic penetration of 
TMR-r13 peptide. MCH58 cells were grown under atmospheric (20% oxygen) or 
hypoxic (2% oxygen) conditions, in the presence or absence of a cocktail of antioxidants. 
Cells were then treated with 1 µM TMR-r13 peptide for 1 hour. Anti-ox corresponds to 
the antioxidant cocktail. NS represents P>0.05, ** represents P≤0.01, and *** represents 
P≤0.001.  
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Figure 2-14. Cytosolic penetration of TMR-r13 peptide is slower in cells grown at 
2% than 20% oxygen. MCH58 cells cultured under 20% O2 were incubated with 5 µM 
TMR-r13 peptide for 1, 3, 5, and 10 min. The cytosolic delivery efficiency of TMR-r13 
was determined by measuring the TMR signal using fluorescence microscope. In parallel, 
the experimental conditions were carried out with cells cultured under 2% O2. Similarly, 
both cells cultured under 20% and 2% O2 were incubated with 1 µM TMR-r13 peptide for 
5, 10, and 15 min. Hypoxia also reduces the amount of peptide penetrating cells, as shown 
by flow cytometry analysis (on the left) of cells incubate with 1 µM TMR-r13 for 10 min. 
FL2-H is signal intensity of sample in the FL2 channel (Ex = 488 nm/Em = 585 ± 40 nm, 
used for detection of TMR-r13). 
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Figure 2-15. Cytosolic penetration of TMR-r9 peptide is abolished in MCH58 cells 
cultured at 2% oxygen. MCH58 cells cultured at 20% or 2% oxygen were incubated with 
1 µM TMR-r9 peptide for 1 hour and imaged using fluorescence microscopy. Acquired 
images are inverted monochromes of TMR fluorescence emission (RFP filter) and 
monochromes of bright field imaging. Scale bars, 20 µm.    
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2.2.4. Increasing oxidation enhances cytosolic penetration of TMR-r13  
If a reduction in oxygen tension decreases cell penetration, one would expect that 
increasing oxidative stress might conversely enhance cellular entry. To test this 
hypothesis, cells were partially oxidized with oxidants and the impact of these reagents on 
penetration was established. In these assays, I used HDF cells because of their lower 
propensity for polyarginine cytosolic penetration (Figure 2-3). Cells were treated with the 
lipophilic oxidant cumene hydroperoxide (cumene-OOH) or with hydrogen peroxide 
(H2O2). The concentration of oxidants was kept low in these experiments in order to not 
impact cell viability and proliferation (Figure 2-16). As tested using the MTT assay, the 
similarity between the proliferation rates of treated versus untreated cells is an indication 
that cells remain relatively healthy after mild oxidation. Treatment with both cumene-
OOH and H2O2 increased the cytosolic penetration efficiency of TMR-r13 peptide (Figure 
2-17). Cumene, a non-oxidant control compound, did not significantly impact TMR-r13 
delivery, indicating that the lipid bilayer insertion of the cumene moiety of cumene-OOH 
is not significantly altering the permeability of the membrane. Moreover, treatment with 
cumene-OOH increased the cytosolic penetration efficiency of TMR-r13, TMR-r11, and 
TMR-r9 peptides at detectable levels (Figure 2-18). However, other polyarginine or 
polylysine CPPs such as TMR-R7 or DEAC-K9 peptide did not penetrate these oxidized 
cells, indicating that the cells are not simply more permeable to all peptides (data not 
shown).  
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Figure 2-16. HDF cells treated with cumene-OOH display a proliferation rate similar 
to untreated cells. HDF cells were challenged with 50 µM cumene-OOH or H2O2 for 30 
min and monitored the proliferation rate by using MTT assay.    
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Figure 2-17. Cell penetration activity of TMR-r13 peptide in HDF cells increases 
significantly in the presence of oxidants. HDF cells were pretreated with lipophilic 
oxidant cumene hydroperoxide (cumene-OOH), cumene, or H2O2 for 30 min and 
incubated with 1 µM TMR-r13 peptide for 1 hour. *** represents P≤0.001, **** 
represents P≤0.0001, and NS represents P>0.05 compared to vehicle (PBS supplemented 
with calcium and magnesium). Scale bars, 20 µm.      
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Figure 2-18. Cumene-OOH increases the activity of TMR-r13, TMR-r11, and TMR-
r9 peptides in a dose-dependent manner in HDF cells. HDF cells were pretreated with 
cumene-OOH (0, 25, or 30 µM) for 30 min and then incubated with the peptides (3 µM) 
for 1 hour. The cytosolic penetration of peptides were quantified by fluorescence 
microscope (histogram) and flow cytometry. NS represents P>0.05, * represents P≤0.05, 
** represents P≤0.01, and *** represents P≤0.001 compared to cells not treated with 
cumene-OOH. FL2-H is the signal intensity of sample in the FL2 channel (Ex = 488 
nm/Em = 585 ± 40 nm, used for detection of TMR).   
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2.2.5. Membrane oxidation correlates with cell penetration of TMR-r13 peptide 
Oxidative stress can result in a broad spectrum of effects. Given that the TMR-r13 
peptide appears to directly cross the plasma membrane of cells, I next chose to determine 
whether membrane oxidation correlates with the efficiency with which the peptide 
penetrates cells. First, I examined whether the conditions utilized in the previous oxidation 
experiments led to changes in membrane chemistry. The lipophilic reporter C11-
BODIPY581/591 was used to quantify the oxidation state of cellular cellular membranes. 
The fluorescence emission of C11-BODIPY581/591 changes from red (595 nm) to green 
(520 nm) upon oxidation210. The susceptibility of C11-BODIPY581/591 to oxidation is 
equivalent to that of endogenous polyunsaturated lipids present in cell membranes; a 
change in fluorescence of this reporter can be used to infer overall lipid oxidation. An 
increase in green fluorescence was observed by both microscopy and flow cytometry when 
cells grown at 20% oxygen were treated with an increasing amount of cumene-OOH (no 
increase was observed with the control compound cumene). This indicates that cellular 
membranes are oxidized by the lipophilic oxidant (Figure 2-19). Notably, the cytosolic 
penetration of TMR-r13 peptide correlated positively with the green fluorescence of C11-
BODIPY581/591 (Figure 2-19), supporting the notion that the oxidized membrane 
components might be involved in the membrane translocation of the peptide.  
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Figure 2-19. Membrane oxidation and cytosolic penetration of TMR-r13 peptide are 
positively correlated. A, HDF cells were treated with cumene-OOH at various 
concentrations (0, 10, 25 or 50 µM) for 30 min and the cytosolic penetration efficiency of 
delivered TMR-r13 peptide (1 µM, 1 hour) was detected. Images of TMR-r13 peptide 
delivery are monochromes of TMR fluorescence emission (RFP filter). In parallel, 
membrane oxidation level after cumene-OOH treatment was measured using the green 
fluorescence of the lipophilic oxidation reporter C11-BODIPY581/591. Scale bar, 20 µm. B, 
Flow cytometry analysis of C11-BODIPY581/591 green fluorescence signal upon oxidation 
of HDF cells. FL1-H corresponds to the signal intensity of sample in the FL1 channel (Ex 
= 488 nm/Ex = 533 ± 30 nm). C, The correlation between the geometric mean of the C11-
BODIPY581/591 emission and the cytosolic penetration efficiency is reported.   
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Since MCH58 cells are more prone to cell penetration than HDF cells (Figure 2-
3), I next examined whether the variation in peptide activity between these two cell types 
could be accounted for by a difference in the overall level of membrane oxidation. The 
previous C11-BODIPY581/591 assay was, however, not sufficiently sensitive to compare 
cells cultured under 20% oxygen, as shown in Figure 2-19 that only a weak C11-
BODIPY581/591 green fluorescence signal is obtained when cumene-OOH is absent. 
Therefore to circumvent this issue, an assay using diphenyl 1-pyrenylphosphine (DPPP) 
was performed instead. DPPP is a non-fluorescent lipophilic compound that reacts 
stoichiometrically with lipid hydroperoxides to yield a fluorescent DPPP oxide211.  The 
MCH58 and HDF cells cultured at 2% or 20% oxygen were incubated with DPPP and the 
fluorescence of DPPP oxide obtained was quantified. The number of cells present in each 
sample was analyzed by flow cytometry. Given that MCH58 and HDF cells have similar 
morphologies and sizes, the DPPP oxide fluorescence was then normalized to the total 
number of cells for comparison. As shown in Figure 2-20, the fluorescence of DPPP oxide 
was significantly greater in cells grown at 20% oxygen than in cells grown at 2% oxygen. 
In addition, MCH58 cells were also consistently more fluorescent than HDF cells under 
similar growth conditions, suggesting higher levels of lipid peroxides in MCH58 cells than 
in HDF cells. Overall, these data indicate a positive correlation between membrane 
oxidation and cell penetration of the peptide.  
 
 47 
 
 
Figure 2-20. The level of lipid peroxides in the membrane of MCH58 cells is higher 
than of HDF cells. The membrane oxidation of cells were compared by using the 
lipophilic DPPP probe. The fluorescence of oxidized DPPP present in cellular membranes 
of cells grown at 2% or 20% oxygen is reported as normalized to the total number of cells 
per sample and to the least oxidized sample (2%, HDF cells). * represents P≤0.05 and ** 
represents P≤0.01.  
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2.3. Discussion 
My results establish that the conditions utilized during cell growth markedly 
impact the permeability of cells for polyarginine CPPs. Under all conditions tested, the 
oxidation index positively correlates with the cell penetration efficiency of examined 
CPPs (Figure 2-21). Given that the translocation of the peptides appears to take place at 
the plasma membrane, it is reasonable to postulate that oxidation alters the properties of 
plasma membrane and that certain oxidized membrane components mediate or facilitate 
the translocation process. Differences in the level of oxidative damage or, conversely, how 
efficiently cells repair oxidative damage, could possibly explain the variability in CPP 
performance from cell to cell, from cell type to cell type, or among various experimental 
conditions (e.g. media with or without antioxidant supplements).    
An important question is whether membrane oxidation is necessary for the 
cytosolic penetration of CPPs or merely facilitates the process. Anaerobic conditions are 
lethal to human cells and suppression of oxidative stress generation by the complete 
removal of oxygen is therefore not testable. In contrast, cells thrive in the environment of 
2% oxygen212, 213. This growth condition was however not sufficient to completely abolish 
the cytosolic penetration of CPPs. In addition, the presence of lipid peroxides was able to 
be detected in the cellular membranes under these conditions, indicating that some level 
of membrane oxidation persists even at a low-oxygen environment. Notably, addition of 
antioxidants showed a more pronounced inhibitory effect on CPP delivery, which is 
presumably by further diminishing the number of oxidized species present at the plasma  
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Figure 2-21. A scheme illustrates the relationship between the cellular penetration 
of CPPs and the membrane oxidation index.   
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membrane. This result would then support the notion that oxidized species are required to 
achieve membrane translocation. In addition, comparison between the TMR-r13 peptide 
and the shorter oligoarginine peptides suggests that the TMR-r13 peptide represents a 
highly active member within a large family of CPPs. If membrane oxidation is critical in 
mediating the translocation activity of the TMR-r13 peptide, it should be even more so for 
the less active peptide. My data support this notion as hypoxia completely inhibited the 
cytosolic penetration of TMR-r9 peptide. I therefore conclude that membrane oxidation is 
essential for the cytosolic penetration by linear oligoarginine CPPs at low micromolar 
concentrations.  
How membrane oxidation mediates peptide penetration at the molecular level 
remains currently unclear. It is possible that membrane oxidation changes the general 
properties of the plasma membrane and that peptide translocation does not directly involve 
oxidized species. For instance, membrane oxidation can alter membrane fluidity and this 
alone could change the permeability of the cell214, 215. In addition, Melikov and co-workers 
have suggested that surface-exposed phosphatidylserine (PS) mediates the translocation 
of polyarginine peptides into cells175. Interestingly, lipid bilayer oxidation has been shown 
to promote the flip-flop of PS, a lipid that is otherwise typically present on the inner leaflet 
of the plasma membrane216. In this context, membrane oxidation might contribute to an 
increase in the amount of PS present on the cell surface and thereby promote peptide 
translocation. Alternatively, oxidized species, including oxidized lipids, could be directly 
involved in interacting with polyarginine peptides and mediate their transport. Oxidation 
chemistry is, however, extremely complex and gives rise to a wide variety of products. 
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For instance, simple exposure of a dry unsaturated phospholipid to air produces a wide 
spectrum of oxidized by-products (> 20 species)189. Non-enzymatic oxidation reactions 
also involve propagation steps that can dramatically amplify the effect of an initial 
oxidation event. This is the case for lipid peroxidation where the abstraction of a single 
hydrogen from a poly-unsaturated fatty acid by reactive oxygen species (ROS) initiates a 
cascade of oxidation reactions that can subsequently damage a large number of 
neighboring lipids within a membrane217. Each lipid peroxide formed in this process can 
then decompose into a multitude of products. The cell counteracts this damage using a 
wide variety of mechanisms, ranging from protection with antioxidants to enzymatic 
repair or degradation192. As a result of this complexity, the identity of oxidized lipids 
present in a membrane and their respective levels remains poorly characterized. This work, 
however, highlights that a thorough examination of how composition of cellular 
membranes changes with oxidation is now required in order to shed light on the 
mechanisms of membrane translocation. 
2.4. Materials and methods 
2.4.1. Peptide synthesis and purification 
All peptides were synthesized by following a Fmoc chemistry-based solid-phase 
peptide synthesis (SPPS) standard protocol. The Rink Amide MBHA resin 
(Novabiochem) was swollen in dimethylformamide (DMF) (Thermo Fisher Scientific) for 
1 hour in a SPPS glass vessel (Chemglass Life Sciences). The resin was activated by 
performing Fmoc deprotection using 20% (v/v) piperidine (Sigma-Aldrich) in DMF. A 
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thorough wash of the activated resin with DMF was applied before amino acid coupling. 
The amino acid Fmoc-Arg(Pbf)-OH (Novabiochem) was dissolved in DMF and activated 
by adding 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium (HBTU, Novabiochem) 
and N,N-Diisopropylethylamine (DIEA, Sigma-Aldrich) to a molar ratio of 4:3.9:10 
(amino acid:HBTU:DIEA). The coupling reaction was carried out by mixing activated 
amino acid to the activated resin under a stream of dry nitrogen gas for at least 4 hours at 
room temperature. The amino acid was extended on the resin by repeating the procedures 
of Fmoc protection removal and amino acid coupling. Fmoc-Arg(Pbf)-OH, Fmoc-D-
Arg(Pbf)-OH, Fmoc-Lys(Boc)-OH, and Fmoc-D-Lys(Boc)-OH (Novabiochem) were 
utilized for synthesizing L-polyarginine peptides (Rn, n = 5, 7, 9, 11, and 13), D-
polyarginine peptides (rn, n = 9, 11, 13), L-polylysine peptide (K9), and D-oligolysine 
peptide (k5), respectively. To visualize the peptides in cell delivery experiments, the 
fluorophore 5(6)-carboxytetramethylrhodamine (TMR) (Novabiochem) or 7-
diethylaminocoumarin-3-carboxylic acid (DEAC) (AnaSpec) was labeled at the N-
terminal amino group of the peptide after Fmoc deprotection. The fluorophores were 
activated by mixing with HBTU and DIEA in DMF to a molar ratio of 2:1.9:5 
(fluorophore:HBTU:DIEA) and were then added to the resin and allowed to react for 24 
hours. To cleave the synthesized peptide off the resin, 4 ml of cleaving solution composed 
of trifluoroacetic acid (TFA) (Sigma-Aldrich), Triisopropylsilane (TIS) (Sigma-Aldrich), 
and deionized distilled water (H2O) (TFA:TIS:H2O = 95%:2.5%:2.5%) was used. The 
resin was transferred to a polypropylene column (Bio-Rad) and mixing vigorously with 
cleaving solution on a shaker for 3 hours. The cleaved peptide solution was then 
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precipitated in a cold anhydrous ethyl ether and collected by centrifugation at 4,000 rpm 
for 10 min at 4oC. To examine the purity of the synthesized peptide, the cleaved crude 
peptide was dissolved in Buffer A (99.9% H2O and 0.1% TFA) and analyzed on reverse-
phase HPLC Agilent 1200 Series system (Agilent) using Vydac C18 column (5-µm 
particle size, 4 mm x 150 mm) with a linear gradient of Buffer A (99.9% H2O and 0.1% 
TFA) and Buffer B (90% acetonitrile, 9.9% H2O, and 0.1% TFA) at a flow rate of 1 
ml/min. The peptide was purified using a semi-prep column, Vydac C18 (10 mm x 150 
mm) at a flow rate of 4 ml/min. The identity of peptide was confirmed by MALDI-TOF 
mass spectrometry analysis (Shimadzu) using α-cyano-4-hydroxycinnamic acid (CHCA) 
(Sigma-Aldrich) matrix. TMR-R13 peptide (TMR-RRRRRRRRRRRRRG-NH2) 
expected mass: 2515.50, observed mass: 2516.95; TMR-R11 peptide (TMR-
RRRRRRRRRRRG-NH2) expected mass: 2203.30, observed mass: 22204.82; TMR-R9 
peptide (TMR-RRRRRRRRRG-NH2) expected mass: 1891.10, observed mass: 1892.96; 
TMR-R7 peptide (TMR-RRRRRRRG-NH2) expected mass: 1578.90, observed mass: 
1579.99; TMR-R5 peptide (TMR-RRRRRG-NH2) expected mass: 1266.70, observed 
mass: 1267.74; TMR-r13 peptide (TMR-rrrrrrrrrrrrr-NH2) expected mass: 2460.94, 
observed mass: 2463.48; TMR-r11 peptide (TMR-rrrrrrrrrrr-NH2) expected mass: 
2147.29, observed mass: 2148.92; TMR-r9 peptide (TMR-rrrrrrrrr-NH2) expected mass: 
1835.09, observed mass: 1835.43; DEAC-K9 peptide (DEAC-KKKKKKKKK-NH2) 
expected mass: 1412.97, observed mass: 1415.59; DEAC-k5 peptide (DEAC-kkkkk-NH2) 
expected mass: 900.59, observed mass: 900.84. The dfTAT peptide were obtained by 
following published protocols17.   
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2.4.2. Protein expression and purification 
The pTXB1-EGFP plasmid encoding EGFP protein was transformed into 
Escherichia coli BL21(DE3) cells (Agilent Technologies). EGFP protein was expressed 
in the cytoplasm of E. coli as a fusion protein containing a C-terminal Intein protein and 
chitin binding domain (CBD) at 16oC for 24 hours. The transformed E. coli cells were 
lysed by sonication with lysis buffer (50 mM HEPES, 200 mM NaCl, pH 7.5) 
supplemented with protease inhibitor cocktail (Sigma-Aldrich). The cell lysate was 
centrifuged at 14,000 rpm for 45 min to remove cell debris. To purify the protein, the 
supernatant was incubated with chitin resin (New England BioLabs) at 4oC overnight. The 
bound proteins were purified by incubating with cleaving buffer (50 mM HEPES, 50 mM 
dithiothreitol, pH 7.5) for 24 hours at 4oC. The cleaved EGFP proteins, which have no 
Intein-CBD tag, were combined and dialysed against 50 mM HEPES buffer using dialysis 
tubing (10 kDa MWCO, Spectrumlabs) to remove excess of salt. The EGFP proteins were 
further purified by anion-exchange chromatography (HiTrap SP HP 5ml, GE Healthcare) 
using AKTA fast protein liquid chromatography (FPLC) system (GE Healthcare) with a 
linear gradient of purification buffer (50 mM HEPES, 0-1000 mM NaCl, pH 7.5) to 
remove protein-bound bacterial nucleic acids and presumably lipopolysaccharides (LPS). 
The purified proteins were combined and concentrated using a centrifugal filter 
concentrator (membrane cut-off size: 10 kDa, Millipore) to the desired concentration. The 
purity of EGFP proteins was checked during the purification procedure by analyzing by 
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the 12% SDS-PAGE with standard Coomassie Brilliant Blue staining (Sigma-Aldrich) or 
fluorescence scanning by Typhoon scanner (GE Healthcare).      
 
2.4.3. Live-cell delivery and imaging 
Human dermal fibroblast (HDF) (ATCC PCS-201-010) and MCH58 cells (human 
skin fibroblast, obtained from E. Shoubridge, Montreal Neurological Institute and 
Hospital) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (HyClone) 
supplemented with 10% (v/v) fetal bovine serum (FBS) (HyClone) and 1x 
penicillin/streptomycin (P/S) (MP Biomedicals)218. For standard cultures (under 20% 
oxygen), cells were placed in an incubator (NuAire) with humidified ambient atmosphere 
containing 5% carbon dioxide at 37oC. Alternatively, for hypoxic cultures (under 2% 
oxygen), cells were grown in a closed camber (modular incubator chamber, Billups-
Rothenberg), which was purged with humidified 2% oxygen, 5% carbon dioxide, and 93% 
nitrogen gas (Praxair) at 20 L/min for 4 min. The chamber was then sealed and placed in 
an incubator at 37oC (Figure 2-22). Cells were subcultured under normoxic (20% oxygen) 
or hypoxic environment (2% oxygen) for at least a week before performing live-cell 
delivery assays. Both normoxically and hypoxically cultured cells were maintained with 
the same passage number throughout all the experiments.  
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Figure 2-22. Hypoxic and normoxic setup for mammalian cell culture. A, Cells were 
placed in a closed chamber flushed with 2% oxygen, 5% carbon dioxide, and 93% 
nitrogen. B, The chamber was deposited in the regular cell culture incubator at 37oC to 
perform hypoxic cell culture. For regular cell culture (normoxic), cells were placed 
directly in the incubator as shown (Top shelf).     
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To perform cell delivery experiments, HDF or MCH58 cells were seeded in 8-well 
chambered glass plate (Nunc) for 24 hours to reach 80-90% cell confluency. Each well of 
cells was washed three times with Dulbecco’s Phosphate Buffered Saline (PBS) 
(HyClone), followed by washing three times with Leibovitz’s L-15 medium (HyClone). 
Cells were then incubated with 1-10 µM peptide in L-15 medium (no supplementation 
with serum) for 1-60 min at 37oC (the peptide concentration and incubation time were 
varied and were dependent on the condition tested in each experiment). To remove 
extracellular and plasma membrane-bound peptides, cells were washed three times with 1 
mg/ml heparin (Sigma-Aldrich) in L-15 medium. Five µM SYTOX Blue (Molecular 
Probes) was added to the cells to monitor the viability after peptide delivery. All images 
were captured by an inverted epifluorescence microscope (Model IX81, Olympus) 
equipped with a Rolera-MGI Plus back-illuminated electron-multiplying charge-coupled 
device (EMCCD) camera (Qimagining). Images were acquired using phase contrast and 
three standard fluorescence filter sets: CFP (excitation (Ex) = 436 ± 10 nm/emission (Em) 
= 480 ± 20 nm), RFP (Ex = 560 ± 20 nm/Em = 630 ± 35 nm), and FITC (Ex = 488 ± 10 
nm/Em = 520 ± 20 nm). The fluorescence intensities of cells were analyzed with 
SlideBook 4.2 software (Olympus).  
 
2.4.4. Cell viability and proliferation assays 
To monitor the permeability of the plasma membrane after peptide delivery or 
oxidant treatment, cells were incubated with the cell-impermeable nucleic acid-staining 
SYTOX Blue dye. The proliferation of treated cells was examined by MTT assay 
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(Molecular Probes) following manufacturer’s instructions. Briefly, cells were cultured in 
a 6-well plate to 80-90% confluency and were treated with 1 µM TMR-r13 for 1 hour or 
50 µM oxidant (cumene-OOH or H2O2) for 30 min at 37
oC. Then cells were washed with 
PBS for three times and were detached by 0.5% trypsin solution (HyClone). Trypsinized 
cells were resuspended in DMEM medium supplemented with 10% FBS and 1x P/S and 
seeded in 96-well plates. The cell proliferation rate was measured every 12 hours. The 
measurement was performed by removing the old DMEM medium in the well followed 
by adding 100 µl fresh DMEM medium and 10 µl of 12 mM 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) solution (Molecular Probes).  The 96-well plate 
was incubated at 37oC for 4 hours. The contents of each well were then mixed thoroughly 
with 100 µl of 10 mM SDS-HCl solution and incubated at 37oC for 12 hours.  The 
formation of formazan from MTT compound catalyzed by cell mitochondrial reductase 
was measured by spectrometry at 560 nm. In parallel, cells incubated with vehicle (either 
PBS supplemented with calcium and magnesium or L-15 medium, depending on the 
reagent tested) served as controls.     
 
2.4.5. Cell penetration mechanism assays 
To inhibit cellular endocytic processes, cells were first washed with warm PBS 
three times and pre-treated with 50 µM amiloride (Sigma-Aldrich) or 200 nM bafilomycin 
A1 (Sigma-Aldrich) for 20 min. Alternatively, cells were washed with cold PBS and pre-
incubated at 4oC for 30 min. Then cells were incubated with 1 µM TMR-r13 peptide with 
presence of the same concentration of inhibitor (50 µM amiloride or 200 nM bafilomycin 
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A1) for 1 hour at 37oC, or at 4oC with TMR-r13 peptide alone for 1 hour. Alternatively, 
cells were pre-loaded with peptide cargo in late endosomes/lysosomes by incubating with 
20 µM DEAC-k5 peptide in L-15 medium for 1 hour at 37oC. Extracellular DEAC-k5 
peptide was removed by washing cells with PBS and heparin solution for three times. The 
DEAC-k5-loaded cells were then incubated with 5 µM TMR-r13 peptide for 1 hour at 
37oC. The cytosolic penetration efficiency of TMR-r13 and DEAC-k5 peptides was 
evaluated by the method described in section 2.4.2. As a control, the peptide cargo-loaded 
cells were treated with 5 µM dfTAT peptide in L-15 medium without cystine for 1 hour 
at 37oC.   
To illustrate the accumulation of incubated peptide in endocytic vesicles, cells 
were incubated with 3 µM TMR-r13 peptide or 20 µM DEAC-k5 peptide for 1 hour at 
37oC. Extracellular peptides were removed by washing the cells three times with heparin 
solution and L-15 medium. LysoTracker Green (500 nM, Molecular Probes) was then 
added to cells for 30 min at 37oC. Cells were washed three times with L-15 medium and 
imaged using the method described in section 2.4.2. 
 
2.4.6. Cell redox treatments 
HDF cells were pre-oxidized with various concentrations of freshly prepared 
oxidants (cumene-OOH or H2O2) in PBS supplemented with 100 mg/L calcium and 100 
mg/L magnesium (PBS+, HyClone) for 30 min at 37oC. In contrast, to reduce cellular 
oxidative stress, cells were cultured in low glucose DMEM supplemented with various 
antioxidants, including 1 mM pyruvate (HyClone), 250 µM α-tocopherol (Sigma-
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Aldrich), 250 µM Trolox (Sigma-Aldrich), 75 µM ascorbic acid (MP Biomedicals), 500 
µM 2-phospho-L-ascorbic acid (Simga-Aldrich), and 100 nM sodium selenite 
(Mallinckrodt Pharmaceuticals) for 48 hours. Medium containing freshly prepared 
antioxidants was added every 24 hours.   
 
2.4.7. Cell membrane oxidation detection 
The C11-BODIPY581/591 probe (Molecular Probes) purchased from the vendor was 
resuspended in pure ethanol to create a stock solution. The probe was diluted in L-15 
medium to 15 µM and was then incubated with the cells for 30 min at 37oC. The 
unincorporated probe was removed by washing the cells with PBS and L-15 medium for 
three times. The cellular oxidized C11-BODIPY581/591 signal was measured by 
fluorescence microscopy using an FITC filter (Ex = 488 ± 10 nm/Em = 520 ± 20 nm), 
followed by quantitative analysis utilizing flow cytometry. The cells for flow cytometric 
analysis were prepared by detaching with 0.5% trypsin solution. The trypsinized cells were 
resuspended in the L-15 medium. The signal of oxidized probe was examined by a flow 
cytometer (BD Accuri C6 model) installed with standard detector FL1 (Ex = 488 nm/Em 
= 533 ± 30 nm) and FL2 (Ex = 488 nm/Em = 585 ± 40 nm). All data was acquired at the 
flow rate of 66 µl/min with a minimum of 20,000 events. The obtained signal was 
statistically analyzed by Flowjo v10 software. Alternatively, the stock solution of DPPP 
(Molecular Probes) was prepared by dissolving DPPP in dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich) under a nitrogen atmosphere and was stored at -20oC. HDF or MCH58 
cells grown in 60-mm culture dish (Corning) were detached with 0.5% trypsin solution 
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and resuspended in L-15 medium. The resuspended cell solution was incubated with 100 
µM DPPP for 5 min and was transferred to 96-well plates. The fluorescence intensity of 
the oxidized DPPP probe was measured by GloMax-Multi Microplate Multimode Reader 
(Promega) equipped with the UV Optical Kit (Ex = 365 nm/Em = 435 ± 25 nm). The 
oxidized DPPP signal was normalized by cell numbers counted using the flow cytometer 
(BD Accuri C6 model). The samples without adding DPPP or cells serve as negative 
controls.  
 
2.4.8. Statistical analysis 
All statistical analyses were performed using Paired Two Sample for Means t-Test 
by Microsoft Excel 2013.  
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3. PRESENCE OF ANIONIC OXIDIZED LIPIDS IS SUFFICIENT TO 
MODULATE MEMBRANE TRANSLOCATION OF POLYARGININE 
PEPTIDE2 
3.1. Introduction 
Previously, I established the correlation between the cell penetration activity of 
polyarginine CPPs and cell membrane oxidation level. The tested oxidants, cumene-OOH 
and H2O2, presumably generate a broad array of lipidic or proteinaceous membrane 
products. Similarly, the transition between 2% and 20% oxygen potentially leads to a 
variety of changes in cellular membrane composition. Identifying which membrane 
components impact translocation, directly or indirectly, will be the focus of this section. 
It has been shown that cationic polyarginine CPPs displayed strong affinity towards 
anionic lipophilic molecules, which mediate the permeation of the peptide into the milieu 
of hydrophobic environment. Therefore, I propose that the generated anionic oxidized 
phospholipids upon membrane oxidation are involved in the membrane translocation of 
polyarginine CPPs.  
 
3.2. Results 
3.2.1. Membrane oxidation promotes peptide binding to the lipid bilayer 
           In principle, the TMR-r13 peptide must interact with a cellular membrane prior to 
                                                 
2 Reprinted with permission from “Membrane oxidation enables the cytosolic entry of polyarginine cell-
penetrating peptides” by Wang, T.-Y., Sun, Y., Muthukrishnan, N., Erazo-Oliverase, A., Najjar, K., and 
Pellois, J.-P., 2016. The Journal of Biological Chemistry, 291(15): 7902-7914. Copyright 2016 by the 
American Society for Biochemistry and Molecular Biology. 
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crossing it. Consequently, I examined whether oxidation could change the overall affinity 
of polyarginine peptide to the membrane. Testing surface binding of a peptide is 
challenging with live epithelial cells because of the competition of cellular endocytic 
uptake. I therefore chose to test how TMR-r13 peptide interacts with human erythrocytes, 
also known as red blood cells (RBCs), as the mature RBCs are not typically competent for 
endocytosis while the cells have similar lipid composition, lipid asymmetry, and 
membrane structures as other mammalian cells219, 220. The RBCs were oxidized with H2O2 
at a low concentration to avoid hemolysis. The oxidized cells were then directly incubated 
with the peptide or were further trypsinized in order to evaluate the importance of 
extracellular protein domains. When incubated with 1 µM TMR-r13 peptide at a peptide 
concentration that is low to prevent hemolysis, the non-oxidized RBCs displayed only a 
faint surface staining of the peptide (Figure 3-1). In contrast, upon oxidation treatment, 
the fluorescence signal of the peptide at RBC membrane increased approximately 5-fold 
(Figure 3-1). The oxidation of RBCs alone did not result in the membrane 
autofluorescence (data not shown). Notably, these results were obtained regardless of 
trypsin treatment, indicating that the extracellular proteins were not required for this 
phenomenon. Together, these data suggested that the interaction of TMR-r13 peptide with 
the lipid bilayer increases upon oxidation, presumably by the formation of oxidized lipid 
species.      
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Figure 3-1. Membrane oxidation increases the binding of TMR-r13 peptide to cell 
surface components. The human RBCs were oxidized by treatment with 50 µM H2O2. 
The cells were then trypsinized, incubated with 1 µM TMR-r13, and imaged with 
fluorescence microscopy. The bright field images of cells with a dark contrast indicates 
that the cells were not lysed, compared to the image of a lysed RBC. The fluorescence 
intensity distribution along the dashed lines is displayed. Scale bar, 2 µm.       
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3.2.2. Cytosolic penetration of TMR-r13 peptide is blocked by an antibody against 
oxidized lipids 
Based on the notion that oxidized lipids might bind to the TMR-r13 peptide and 
participate in its translocation across a lipid layer, I next examined whether biomoleucles 
that interfere with oxidized lipids on the cell surface might inhibit the cytosolic 
penetration. To test this hypothesis, an E06 monoclonal antibody (E06 mAb) was used. 
The E06 mAb binds to several byproducts of the oxidation of phosphatidylcholine, often 
referred to as Ox-PC221. Considering that phosphatidylcholine (PC) is a major component 
of the outer leaflet of the plasma membrane, it seemed to be reasonable that this antibody 
would be sufficient to display an effect222. MCH58 cells were pretreated with 50 µg/ml 
E06 mAb or a control IgM monoclonal antibody that does not target oxidized lipids (its 
epitope is advanced glycation end products)223. The phosphorylcholine salt (PC salt) was 
also premixed with E06 mAb, as this molecule inhibits the binding of E06 mAb to the 
polar head of Ox-PC224. The IgM and the combination of E06 mAb/PC salt did not impact 
the cytosolic penetration activity of TMR-r13 peptide (Figure 3-2). In contrast, E06 mAb 
caused a significant reduction in cytosolic penetration, suggesting that the Ox-PC might 
be directly or indirectly mediating the activity of TMR-r13 peptide.  
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Figure 3-2. Anti-oxidized lipids antibody E06 inhibits cytosolic penetration of TMR-
r13 peptide. MCH58 cells were pre-incubated with IgM (50 µg/ml), phosphorylcholine 
salt (PC salt, 20 µg/ml), E06 mAb (50 µg/ml), or E06 mAb plus PC salt. Cells were then 
delivered with 1 µM TMR-r13 peptide for 10 min. The cytosolic penetration efficiency of 
the peptide was measured by fluorescence microscopy and quantified. The acquired 
images are monochromes of TMR fluorescence emission (RFP filter). Scale bar, 20 µm. 
NS represents P>0.05 and ** represents P≤0.01 compared to cells treated with TMR-r13 
peptide alone.     
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3.2.3. Anionic oxidized lipids mediate the lipid bilayer translocation of 
polyarginine peptides 
Arginine-rich peptides are known to interact promiscuously with negatively 
charged molecules52. I therefore considered whether membrane oxidation might lead to 
the presence of such a species on the surface of cells. This can, for instance, take place by 
oxidation-induced flip-flop of phosphatidylserine (PS) from the inner to the outer leaflet 
of a bilayer216, by the reaction of the lipid head of phosphatidylethanolamine (PE) with 
aldehydes generated upon fatty acid peroxidation225, or by the degradation of lipid 
peroxides and the introduction of carboxylates within lipid fatty acid chains189. These 
mechanisms are not mutually exclusive and each could be directly or indirectly impacted 
by E06 mAb. I therefore chose to examine the behavior of TMR-r13 peptide in the 
presence of 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), of the naturally 
occurring negatively charged adduct formed between 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) and the oxidation by-product malondialdehyde (MDA) 
(DOPE-MDA), or of 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine (PGPC) and 1-
palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PazePC), two lipids obtained upon 
oxidation of PC containing C-5 or C-9 unsaturated fatty acids, respectively189. To test 
whether such species can interact with the TMR-r13 peptide and mediate its transport 
across a lipid bilayer, I tested how these lipids impact the partitioning of the peptide 
between PBS and hexanes. In this assay, hexanes are used to mimic the environment of 
low dielectric constant of the lipid bilayer. As shown in Figure 3-3, TMR-r13 is present 
in the aqueous phase when incubated by itself or in the presence of the zwitterionic lipids 
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1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and DOPE. In contrast, the peptide 
partitions into hexanes in the presence of DOPS or DOPE-MDA (Figure 3-3). This result 
is indicative of inverted micelle formation where the amphiphilic anion is capable of 
shielding the charges of the peptide and mediating its transfer into the hydrophobic 
milieu52. The results obtained with either PGPC or PazePC were more complex. Both 
PGPC and PazePC were insoluble in the hexanes and therefore no partitioning of the 
peptide can be observed. However, the partitioning into hexanes was achieved when 
PGPC or PazePC were mixed with an excess of DOPC, suggesting that the anionic 
oxidized lipids mediate the binding to the cationic peptide while the zwitterionic lipid 
contributed to the formation of inverted micelles (Figure 3-3). This model is supported by 
the result that no translocation of the peptide was observed, when replacing anionic 
oxidized lipids with their zwitterionic analogs, 1-palmitoyl-2-(5’-oxo-valeroyl)-sn-
glycero-3-phosphocholine (POVPC) and 1-palmitoyl-2-(9’-oxo-valeroyl)-sn-glycero-3-
phosphocholine (PoxnoPC) (Figure 3-3). Finally, the propensity of the peptide to partition 
into hexanes in the presence of anionic oxidized lipids was inversely proportional to the 
number of arginine residues present, consistent with their cytosolic penetration activities 
(Figure 3-4).  
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Figure 3-3. Anionic lipids mediate the transfer of TMR-r13 peptide from an aqueous 
phase to a milieu of low dielectric constant. A, The TMR-r13 peptide (5 µM) was diluted 
in PBS (pH 7) and an equal volume of hexanes containing 3 mM lipids was added and 
mixed. The shown structures are the lipid head of phospholipids tested in the assay. The 
amount of peptide equilibrating between each phase after mixing was quantified by 
fluorescence spectrometry. B, The graph represents the relative fraction of peptides 
present in the aqueous and organic phase. DOPC was pre-mixed with PGPC or PazePC at 
a molar ration of 9:1.      
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Figure 3-4. Anionic oxidized lipid-mediated partitioning of linear polyarginine 
peptide is arginine content dependent. Partitioning of 5 µM TMR-Rn (n = 3-13) peptide 
in PBS/hexanes was supplemented with DOPC:PGPC (9:1, 3 mM total lipid 
concentration).      
 
 
 
 
 
 
 
 
 71 
 
To test the plausibility of oxidized membrane components mediating cytosolic 
entry of the peptide, I chose to establish whether the oxidized lipids identified above could 
facilitate membrane translocation. For this assay, DOPS and DOPE-MDA could not be 
incubated with cells without causing cytotoxicity. In contrast, PGPC and PazePC are 
water-soluble and can be tolerated by cells at low concentrations and with a short 
incubation time226. I therefore tested how these anionic phospholipids would alter the 
activity of TMR-r13 peptide upon addition to the growth media. PGPC and PazePC (37.5 
µM) were first pre-incubated with HDF cells for 15 min. Cells were then washed to 
remove extracellular unincorporated lipids and the penetration activity of TMR-r13 
peptide was subsequently tested. I incubated with cells at 1 µM for 10 min, the peptide 
displayed poor penetration in cells treated with vehicle alone (PBS+ only, no oxidized 
lipids added) (Figure 3-5). In contrast, cells treated with PGPC and PazePC showed a 
significant increase in peptide penetration activity without impacting the cell viability 
(Figure 3-5). Overall, these results establish that these oxidized species can enhance the 
cytosolic penetration activity of TMR-r13 peptide and that, given the partitioning results 
obtained, the lipids mediate this effect by directly interacting with the peptide.  
 72 
 
 
Figure 3-5. The oxidized lipids PGPC and PazePC promote the cytosolic penetration 
of TMR-r13 peptide. HDF cells were pretreated with the lipids, followed by washing, 
and then incubated with 1 µM TMR-r13 for 10 min. The vehicle was PBS+. * represents 
P≤0.05 and **** represents P≤0.0001 compared to vehicle. Representative bright field 
images and monochrome images of TMR fluorescence emission (RFP filter) are shown. 
Scale bar, 20 µm. 
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3.3. Discussion 
In order to gain mechanistic insights into oxidation-dependent cell penetration of 
TMR-r13, I decided to test whether pure, physiologically relevant oxidized lipids could 
modulate the activity of TMR-r13 peptide. Several reports have already highlighted that 
anionic amphiphiles can enhance the translocation of polyarginine peptides by acting as 
lipophilic counterions. Pyrenebutyrate can, for instance, be used as an extracellular 
additive that improves the cell penetration of nona-arginine peptide (R9)100. Other anionic 
amphiphiles have displayed similar behavior14, 52, 56, 80. A proposed mechanism of action 
involves the formation of anionic oxidized lipids. To test this idea, two lipids formed as a 
result of oxidative processes were tested: PGPC and PazePC. These two lipids were 
chosen because they are physiologically relevant and produced under oxidative stress in 
vivo. Both lipids contain a carboxylate with which arginine residues can potentially 
interact electrostatically52. Finally, they are relatively water-soluble and can equilibrate 
between the aqueous phase and cell membranes when added to growth media. When tested 
with live cells, both PGPC and PazePC enabled the translocation of TMR-r13. In principle, 
addition of these lipids could have numerous effects and, as noted above, influence cell 
penetration directly or indirectly. Yet, these lipids also mediated the partitioning of TMR-
r13 into hexane, a solvent of low dielectric constant that mimics the hydrophobic 
environment of a lipid bilayer. Together, these data show that TMR-r13 binds to PGPC 
and PazePC and that lipid and peptide form structures that can exist in a hydrophobic 
environment (e.g. inverted micelles). In principle, these oxidized lipid species are 
therefore capable of transporting polyarginine peptides across membranes by direct 
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interactions. Overall I propose that oxidized lipids with similar properties to PGPC and 
PazePC might act as direct mediators of membrane translocation. Based on the 
aforementioned chemical complexity intrinsic to the process of membrane oxidation, this 
could include a broad variety of species that work in concert to facilitate peptide transport. 
Taken together, my results support a novel model for cytosolic penetration where 
arginine-rich peptides translocate across the plasma membrane of cells by interacting with 
anionic phospholipids present on the cell surface as a result of oxidative stress (Figure 3-
6, the whisker model is used to represent the oxidized lipids containing truncated anionic 
fatty acyl chains exposed on the surface of the bilayer)227. Oxidative conditions, including 
high oxygen concentration, presence of oxidants, or lack of antioxidants, can increase the 
number of anionic species present on the cell surface by a number of mechanisms189. This 
then leads to an increase in membrane association by the peptide such as TMR-r13, 
followed by the transfer of peptide into the lipid layer. The transport of peptide across the 
membrane is presumably driven in part by the concentration gradient existing between the 
outside and the inside of the cell. The formation of inverted micelles between peptide and 
anionic phospholipids, including oxidized lipids, are the plausible structures that can 
mediate the peptide translocation without generating membrane leakage. Notably, short 
polyarginine peptides that poorly penetrate the cells do not form inverted micelles with 
anionic phospholipids in my partitioning assays while longer peptides that enter cells do 
(Figure 2-2 and 3-4). The agreement between in cellulo and in vitro assays therefore 
further supports the model presented in Figure 3-6. This model is consistent with other 
proposed membrane translocation models that involves anionic molecules, such as fatty 
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acids and pyrenebutyrate14, 228. An important distinction however is that membrane 
oxidation can explain how anionic lipids are naturally presented on the cell surface. It is 
possible that CPPs also exploit the hydrophobic or hydrophilic defects existing in the 
bilayer (e.g. changes in membrane fluidity and lipid packing) known to increase the 
permeabilization of oxidized membranes194, 201. Such effects could in principle synergize 
with inverted micelle formation and further facilitate translocation.   
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Figure 3-6. Proposed model for the oxidation-dependent cytosolic penetration of 
polyarginine peptide. A simplified lipid bilayer is represented with only the lipids of PC, 
PS, PE-MDA, and PGPC. The polyarginine peptide is expressed as a string of positive 
charges. Under low oxidative stress, the surface of the lipid bilayer is neutral, resulting in 
no binding and no cytosolic penetration from the peptide. At high oxidative stress, anionic 
lipids are present that promote the binding, inverted micelle formation and membrane 
translocation of the peptide.  
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3.4. Materials and methods 
3.4.1. Membrane binding assay 
Whole human blood purchased from Gulf Coast Regional Blood Center (Houston, 
Texas) was centrifuged at 1500 g for 5 min to separate the erythrocytes from the buffy 
coat and the plasma. The obtained erythrocyte pellet was resuspended in cold PBS; this 
procedure was repeated three times. The erythrocytes were treated with 0.1% trypsin 
(HyClone) in PBS at 37oC for 30 min in order to remove the extracellular domains of 
proteins at the plasma membrane. The trypsinized red blood cells (tRBCs) were then 
washed with PBS for five times. The 0.05% tRBCs diluted in the PBS were incubated 
with 50 µM H2O2 for 10 min at room temperature. The oxidized tRBCs were then mixed 
with 1 µM TMR-r13 in a 384-well plate (µ-Plate 384 well, ibidi) on a heating stage at 
37oC for 15 min. The images were acquired by the microscope (Model IX81, Olympus) 
using an 100X objective. The fluorescence intensity of erythrocytes was analyzed using 
SlideBook 4.2 software. The bright field was utilized to distinguish the intact RBCs (dark 
contrast) from lysed RBC ghosts (transparent). All experiments were performed under 
conditions of minimal hemolysis as membrane rupture during lysis leads to exposure of 
PS, which would result in the peptide binding irrespective to membrane oxidation229.      
3.4.2. Anti-Ox-PC antibody treatment 
The anti-oxidized PC E06 monoclonal antibody (E06 mAb, Avanti Polar Lipids) 
was diluted in L-15 medium to a final concentration of 50 µg/ml and then was incubated 
with MCH58 cells for 2 hours at 37oC. After washing the antibody-treated cells with PBS 
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and L-15 medium three times, the cells were incubated with 1 µM TMR-r13 in L-15 
medium for 10 min at 37oC. Heparin (1 mg/ml, Sigma-Aldrich) in L-15 medium wash was 
applied three times to remove excess and membrane-bound peptides. The cell images were 
recorded as described in the previous section. The anti-AGEs mouse IgM κ (ab18400, 
abcam), the same isotype with E06 mAb, serves as a negative control223. To inactivate E06 
mAb, the antibody was pre-mixed with 20 µg/ml phosphorylcholine salt (PC salt, Thermo 
Fisher Scientific) in L-15 medium before incubating with the cells.  
 
3.4.3. Partitioning assay 
Anhydrous DOPC (Avanti Polar Lipids) lipid film was prepared and resuspended 
in hexanes by sonication for 10 min. Alternatively, PGPC or PazePC (Avanti Polar Lipids) 
was dissolved in 1-octanol (Sigma-Aldrich) and was mixed with DOPC solution to a molar 
ratio of 9:1 (DOPC:PGPC or DOPC:PazePC). The partitioning was performed by adding 
3 mM lipid solution to an equal volume of 5 µM peptide in PBS (pH 7) in a 
microcentrifuge tube and mixing vigorously. The fluorescence signal of the peptides in 
either organic or aqueous phase was quantified by GloMax-Multi Microplate Multimode 
Reader (Promega) with Green Optical Kit (Ex = 525 nm/Em = 610 ± 30 nm).  
 
3.4.4. Cell redox treatment  
To feed cells with oxidized phospholipids, a lipid suspension was first prepared. 
PGPC or PazePC stock solution in chloroform was dried under a nitrogen stream to obtain 
a lipid film. The film was placed in a desiccator under vacuum overnight to eliminate any 
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trace of solvent. The dry lipid film was resuspended in PBS+ by sonication for 10 min. 
The 37.5 µM PGPC or  PazePC solution was incubated with HDF cells and incubated for 
15 min at 37oC. Cells were washed three times with PBS+ and L-15 medium, followed by 
incubation with 1 µM TMR-r13 for 10 min at 37oC. The delivery efficiency of peptides 
was measured by fluorescence microscopy as described in the previous section.  
 
3.4.5. Statistical analysis 
All statistical analyses were performed using Paired Two Sample for Means t-Test 
by Microsoft Excel 2013.  
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4. CONCLUSION3
4.1. Summary of results 
I examined the interplay between cellular oxidation and cytosolic penetration of 
peptides using polyarginine CPPs as model compounds. I showed that the cytosolic 
penetration of nona- or trideca-arginine CPPs (r9 and r13 where r is D-Arg, an unnatural 
arginine residue used to confer protease-resistance to the peptide) was abolished or 
significantly reduced, respectively, when cells were cultured at 2% oxygen as opposed to 
20% oxygen. Cell penetration was also reduced when the cellular growth media was 
supplemented with antioxidants. Together, these results indicated that reducing oxidative 
cellular stress diminishes the transport of polyarginine CPPs into cells. Conversely, an 
increase in the oxidation state of the plasma membrane of cells led to an increase in 
polyarginine CPP cytosolic penetration. For instance, r13 efficiently entered cells 
pretreated with lipophilic oxidants (oxidation conditions were mild and did not affect cell 
viability and proliferation rates). Overall, the penetration activity of polyarginine CPP 
positively correlates with the oxidation status of the membrane of cells. 
Given that lipids are possible targets of both oxidative damage and potential 
cellular factors interacting with polyarginine CPPs, I next tested whether oxidized lipids 
might be involved in the oxidation-dependent translocation of the peptides. I observed that 
3 Reprinted with permission from “Peptide translocation through the plasma membrane of human cells: 
can oxidative stress be exploited to gain better intracellular access?” by Wang, T.-Y. and Pellois, J.-P., 
2016. Communicative & Integrative Biology. Copyright 2016 by Taylor & Francis Group. 
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E06, a monoclonal antibody that binds oxidized phosphatidylcholine (oxPC) lipids, 
blocked the intracellular delivery of polyarginine CPP after a simple pre-incubation with 
cells. Furthermore, extracellular addition of the anionic oxPC lipids, PGPC or PazePC, 
enhanced the cytosolic penetration of polyarginine CPPs. Notably, an in vitro partitioning 
assay established that both PGPC and PazePC can transport polyarginine CPPs into a 
milieu of low dielectric constant. This, in turn, is consistent with the notion that 
polyarginine CPPs and anionic oxPC species have the ability to form structures, most 
likely inverted micelles, that allow transfer of the hydrophilic peptide across a 
hydrophobic lipid bilayer.     
 
4.2. Proposed model based on current data 
My results support a novel model for cytosolic penetration where arginine-rich 
peptides translocate across the plasma membrane of cells by interacting with anionic lipids 
exposed on the cell surface as a result of oxidative membrane damage. In particular, 
oxidized lipids might act as direct mediator of peptide transport. In agreement with the 
lipid whisker model, lipid oxidation leads to the formation of anionic truncated fatty acid 
moieties that become exposed on the cell surface (Figure 4-1)227. PACPPs interact with 
these moieties and inverted micelles form between cationic peptide and anionic lipids. The 
concentration gradient generated during incubation (e.g. micromolar concentration of 
peptide outside cells and no CPP inside cells at initial incubation conditions) as well as 
the membrane potential may then drive the accumulation of PACPPs inside cells. 
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Figure 4-1. Membrane oxidation can lead to the exposure of anionic phospholipid on 
the cell surface. In this illustration, the oxidation of arachidonic fatty acid of PAPC yields 
POVPC. Further oxidation of POVPC forms PGPC. The carboxylate formed is negatively 
charged and exposed on the surface of the bilayer. The chemical structure of the lipid head 
and newly formed anionic fatty acyl chain of PGPC is shown and labeled with dark brown 
and green spheres accordingly. 
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4.3. Other possible models connecting lipid oxidation and cell penetration 
            The involvement of oxidized phosphatidylcholine (oxPC) lipids such as PGPC and 
PazePC provide a plausible explanation for peptide translocation. Yet, due to the 
complexities of cell membrane composition and oxidation chemistry, it is likely that other 
oxidized lipids or that other oxidation-dependent processes might also play a role. Below, 
I present alternative and non-mutually exclusive scenari that might also provide a 
molecular basis for the oxidation-dependent behavior of polyarginine CPPs. Melikov and 
co-workers have proposed that phosphatidylserine (PS), an anionic phospholipid normally 
present in human cell membrane may mediate the translocation of polyarginine CPPs175. 
This lipid typically resides in the inner leaflet of mammalian plasma membrane and 
whether polyarginine CPPs can interact with PS on the cell surface remains therefore 
unclear. Yet, it has been established that membrane oxidation can disrupt the lipid 
asymmetry of biological lipid bilayers and that the level of PS exposed extracellularly can 
increase during membrane oxidation216. It is therefore possible that upon membrane 
oxidation, PS partially and transiently relocalizes to the outer leaflet of the plasma 
membrane. It might then bind polyarginine CPPs electrostatically and assist their 
membrane translocation in a micelle-dependent manner similar to that described for 
oxPCs (Figure 4-2). In this scenario, oxidation does not lead to the formation of new 
species, but simply influences the level at which an anionic lipid is exposed on the cell 
surface. 
            Another possible scenario relates to the fact that oxidation of polyunsaturated 
fatty acids generates a wild array of oxidized species, including aldehydes such as  
 84 
 
 
Figure 4-2. Externalization of PS upon membrane oxidation. A simplified lipid bilayer 
is represented with only the phospholipid phosphatidylcholine (PC) and 
phosphatidylserine (PS). The PS asymmetry of the lipid bilayer, maintained by flippases 
in the plasma membrane of human cells, is potentially disrupted upon membrane 
oxidation. The chemical structure of the lipid head of PC and PS are shown in the box and 
labeled with dark brown and red spheres, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 85 
 
malondialdehyde (MDA)189. The formation of MDA is in fact often used as a quantitative 
measure of cellular oxidative stress. In addition, MDA reacts with the amino groups of 
biomolecules to form Schiff-base230. In particular, MDA can react with 
phosphatidylethanolamine (PE), a phospholipid containing a positively charged amine in 
its polar head225. Notably, while PE is zwitterionic, a PE-MDA adduct is anionic (reaction 
with the amino group removes the positive charge of this functional group, leaving a single 
negative charge on the phosphate). Thus, the by-products of lipid oxidation can lead to the 
formation of an anionic lipid on the cell surface. This anionic lipid represents therefore 
another target for possible polyarginine CPP binding and translocation (Figure 4-3).  
              It is also possible that polyarginine CPPs, in addition to binding anionic lipids, 
exploit oxidation-induced hydrophobic or hydrophilic defects present in the bilayer. 
Membrane defects can, for example, be formed upon generation of lipids containing 
truncated fatty acyl chain (anionic or non-anionic). Such species are formed as a 
consequence of lipid peroxidation and of repair by detoxifying enzymes (eg: 
phospholipase A2)231. These oxidized lipids have an inverted cone shape and detergent-
like properties. These species form membrane microdomain and change membrane 
dynamics (e.g. membrane fluidity and lipid packing). These changes are thought to 
increase the permeability of membranes (Figure 4-4)232, 233. Overall I propose that these 
effects could in principle synergize with inverted micelle formation and further facilitate 
translocation of polyarginine CPPs (Figure 3-6).  
              Overall, the models described herein are speculative and have not been tested to 
date. Yet, preliminary results, presented in Figure 3-3, suggest that PGPC, PazePC, PS,  
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Figure 4-3. Oxidation-dependent modification of the polar heads of lipids. PE-MDA 
production is used as an example. MDA is created upon oxidation of polyunsaturated fatty 
acids. The generated MDA reacts with the amino group of the zwitterionc lipid 
phosphatidylethanolamine (PE) to form PE-MDA adduct, an anionic species. The 
chemical structure of the lipid head of PE and PE-MDA is shown and labeled with yellow 
green and cyan spheres, respectively. 
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Figure 4-4. Generation of lysophospholipids and membrane defects upon oxidation. 
Oxidation of PC is given as an example. The unsaturated fatty acid of PC is oxidized to 
form lipid peroxide. Phospholipase A2 (PLA2) cleaves the oxidized fatty acid. The 
generated lyso-phosphatidylcholine (lyso-PC) induces the formation of microdomain, 
leading to alterations in membrane packing, membrane curvature, fluidity, and 
permeability. 
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and PE-MDA all share a similar behavior in vitro. In particular, a simple partitioning assay 
between water and hexane, show that PGPC, PazePC, PS, and PE-MDA can mediate the 
transfer of r13 into a milieu of low dielectric constant while the neutral oxidized lipids 
POVPC and PoxonPC can not. In principle, all these anionic lipids are capable of 
interacting with polyarginine CPPs and bringing them in an environment resembling the 
lipid bilayer. It is therefore possible that several anionic lipid species, while concomitantly 
generated during oxidative stress, might act in concert to interact with polyarginine CPPs 
during cell penetration. 
 
4.4. Implications for cell culture experiments 
        The oxidation-dependent activity of polyarginine CPPs can explain the variations 
often observed in polyarginine CPP performance in live cell delivery experiments. As 
described herein, differences in delivery efficiency can arise from distinct oxidation levels 
of the cell membrane that are generated by exogenous and endogenous factors. Cell culture 
conditions and media composition can impact cell metabolism and oxidative stress levels. 
For instance, the antioxidant ascorbic acid (i.e. vitamin C) is present in certain cell culture 
media but not in others (for example, ascorbic acid is present in CMRL-1066 medium but 
not in the commonly used media DMEM)199. In addition, selenium is a cofactor that is 
essential to the activity of glutathione peroxidase, an enzyme that protect cells from 
oxidative damage and educes lipid hydroperoxides. Selenium is typically introduced in 
cell cultures by addition of serum. Yet, the amount of selenium in serum varies from batch 
to batch and from brand to brand234. These variations have been shown to significantly 
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impact the activities of enzymes involving in antioxidant defense pathways234. It is 
therefore conceivable that variations in growth conditions lead to variations in plasma 
membrane oxidation and in peptide translocation.  
       The oxidation-dependent activity of polyarginine CPPs can explain the variations 
often observed in polyarginine CPP performance in live cell delivery experiments. As 
described herein, differences in delivery efficiency can arise from distinct oxidation levels 
of the cell membrane that are generated by exogenous and endogenous factors. Cell culture 
conditions and media composition can impact cell metabolism and oxidative stress levels. 
For instance, the antioxidant ascorbic acid (i.e. vitamin C) is present in certain cell culture 
media but not in others (for example, ascorbic acid is present in CMRL-1066 medium but 
not in the commonly used media DMEM)199. In addition, selenium is a cofactor that is 
essential to the activity of glutathione peroxidase, an enzyme that protect cells from 
oxidative damage and educes lipid hydroperoxides. Selenium is typically introduced in 
cell cultures by addition of serum. Yet, the amount of selenium in serum varies from batch 
to batch and from brand to brand234. These variations have been shown to significantly 
impact the activities of enzymes involving in antioxidant defense pathways234. It is 
therefore conceivable that variations in growth conditions lead to variations in plasma 
membrane oxidation and in peptide translocation.  
             Similar oxidation-related principles might explain why certain cell types are more 
resistant to peptide penetration than others. For instance, it is interesting to note that 
endogenous level of antioxidants and activities of antioxidation enzymes differ in various 
cell types235. Whether these differences lead to changes in plasma membrane compositions 
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and structures has not been explored. Yet, one can envision how cells displaying low 
oxidative damage at the plasma membrane because of a highly active antioxidative 
defense system would be less susceptible to polyarginine CPP penetration than cells more 
prone to oxidation236. Finally, the level of lipid peroxides present in cells increases with 
the number of passages used in a particular cell culture237. It is therefore possible that cells 
with high passage numbers (“old” cells) differ significantly from freshly cultured cells 
(“young” cells) in their responses to polyarginine CPP treatment. 
              Many parameters can impact the oxidative status of the cell and this, in turn, will 
influence peptide translocation outcomes. When comparing the activity of different 
polyarginine CPPs, controlling membrane oxidation is therefore important as different 
experimental settings might lead to highly variable results. Moreover, favoring mild 
oxidative cell culture conditions might lead to improvements in polyarginine CPP-based 
delivery applications. However, excessive oxidative damage at the plasma membrane can 
severely alter cell physiology. Overall, cell culture conditions optimal for both 
polyarginine CPP delivery and cell biology remain to be established. 
 
4.5. Implications for in vivo applications 
               It is also not clear how the insights I have gained with in vitro experiments might 
apply to how polyarginine CPPs behave in vivo. This is in part because it is hard to 
measure or predict what the in vivo oxidation status of cells is. One can, however, envision 
how a polyarginine CPP that penetrates cells efficiently in vitro might not do so in vivo 
simply because in vivo tissues are better protected from oxidative damage (e.g. cells grown 
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at 20% oxygen vs. tissue exposed to 2% oxygen in vivo). This would then suggest that 
cytosolic penetration studies should not be performed with cells grown under oxidative 
stress (i.e. ambient air) when a goal is to develop cell-permeable peptides for therapeutic 
applications. In particular, assays performed with cells protected from oxidation (e.g. 
culture at 2% rather than 20% oxygen) might offer better predictions for how such peptides 
might perform in vivo. Yet, this issue is complicated by the fact that certain tissues are 
more prone to oxidation than others. For instance, airways are exposed to 20% oxygen. 
Inflamed tissues and tumors are also sites of elevated oxidative stress189, 190. How CPPs 
behave in these tissues based on in vitro data is again hard to predict. Yet, it is possible 
that CPPs have the ability to more readily permeate cells in these environments. 
 
4.6. Future prospects 
    More molecular details are still needed to fully elucidate how polyarginine CPPs 
enter cells. It is plausible that polyarginine CPPs enter cells by multiple routes while 
associating with a wide variety of cellular species. Herein, I describe how several oxidized 
lipid species might play equal roles in this process. The anionic lipids presented are, 
however, not exclusive candidates and other oxidized species might be involved in the 
process of peptide translocation. Further testing of the hypotheses described herein will 
require a thorough examination of the composition of the plasma membrane of cells under 
various conditions of oxidative stress, something that is currently lacking. Useful 
protocols for the analysis of oxidized lipids by mass spectrometry have been developed238. 
Sample preparation remain however a challenge. It is for instance important to protect 
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samples from oxidation during analysis so as to not generate artifacts. In addition, 
selectively purifying the components of the plasma membrane from other cellular 
membranes is not trivial (one can for instance envision that the membrane of mitochondria 
contains oxidized lipids that are not present in the plasma membrane and vice versa). 
Techniques that involve the formation and purification of plasma membrane vesicles 
might be useful in this respect239. However, given that oxidized lipids display a wide range 
of biophysical properties, it is not clear whether a single purification scheme can capture 
all the species present in the plasma membrane. For instance, while many oxidized lipids 
are lipophilic, others are water-soluble. It is therefore possible that these oxidized lipids 
equilibrate in solution during purification and that they do not partition in the organic 
solvents typically used to separate lipids from other cell components. To circumvent some 
of these problems, I am currently developing pull-down protocols, using TMR-r13 as a 
bait for lipid enrichment. While this approach will not identify all the oxidized lipids 
present in the plasma membrane, it might help establish which species interact with the 
peptide during translocation.  
While much remains to be done to reveal how a highly hydrophilic and charged 
peptide such as TMR-r13 crosses a hydrophobic membrane, the interplay between 
cytosolic penetration and oxidation presented herein should have immediate implications. 
For instance, inducing oxidative damage to cellular membranes might offer a novel 
strategy to improve the cell permeability of therapeutic peptides. As indicated by 
experiments involving co-incubation with PGPC or PazePC, formulations that include 
CPPs and oxidized lipids might represent one such strategy.  
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